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Abstract
The leishmaniases comprise a complex of diseases characterised by clin-
ical outcomes that range from self-limiting to chronic, disfiguring and stig-
matising, to life-threatening. Diagnostic methods, treatments, and vector
and reservoir control options exist, but deciding the most effective interven-
tions requires a quantitative understanding of the population level infection
and disease dynamics. The effectiveness of any set of interventions has to
be determined within the context of operational conditions, including eco-
nomic and political commitment. Mathematical models are the best available
tools for studying quantitative systems crossing disciplinary spheres (biology,
medicine, economics) within environmental and societal constraints.
In 2005, the World Health Assembly and government health ministers
of India, Nepal, and Bangladesh signed a Memorandum of Understanding
to eliminate the life threatening form of leishmaniasis, visceral leishmaniasis
(VL), on the Indian subcontinent by 2015 through a combination of early
case detection, improved treatments, and vector control. The elimination
target is <1/10,000 population at the district or subdistrict level compared
to the current 20/10,000 in the regions of highest transmission.
Towards this goal, this chapter focuses on mathematical models of VL,
and the biology driving those models, to enable realistic predictions of the
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best combination of interventions. Several key issues will be discussed which
have affected previous modelling of VL and the direction future modelling
may take. Current understanding of the natural history of disease, immunity
(and loss of immunity), as well as stages of infection and their durations are
considered particularly for humans, but also for dogs. Asymptomatic and
clinical infection are discussed in the context of their relative roles in Leish-
mania transmission, as well as key components of the parasite-sandfly-vector
interaction and intervention strategies including diagnosis, treatment and
vector control. Gaps in current biological knowledge and potential avenues
to improve model structures and mathematical predictions are identified.
Underpinning the marriage between biology and mathematical modelling,
the content of this chapter represents the first step towards developing the
next generation of models for VL.
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1. Introduction
1.0.1. Geographical distribution and disease burden
Endemic transmission of visceral leishmaniasis (VL) occurs in 79 countries
on 5 continents where >58,000 new cases are officially reported each year;
adjusted by the estimated levels of under-reporting (1.2- to 8.0-fold), the true
annual case incidence is likely to be closer to 0.2-0.4 million (Alvar et al.,
2012). Worldwide, 2.35 (95% C.I. 2.18-4.90) million disability-adjusted life
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years (DALYs) are lost due to leishmaniasis, placing leishmaniasis second in
mortality and fourth in morbidity burden among tropical diseases, where VL
is ranked as the second largest parasitic killer after malaria (Mathers et al.,
2007; Hotez et al., 2014).
Most (90%) VL cases occur in 6 countries: India, Bangladesh, Sudan,
South Sudan, Brazil and Ethiopia (Alvar et al., 2012), and 60% of the global
VL disease burden is on the Indian subcontinent (ISC) (WHO, 2002), where
intense transmission is localised in Bihar state and Bengal (NE India), in the
neighbouring Terai region of SE Nepal, and in the Mymensingh district in
Central and West Bangladesh (Alvar et al., 2012). In Latin America, VL is
less geographically focal, traditionally rural but with recent expansion into
urbanised areas, notably in Brazil where approximately 90% of all VL cases
in the Americas occur (Maia-Elkhoury et al., 2008).
1.0.2. Aetiological agents and transmission cycles
Leishmaniasis in humans is caused by more than 20 species of vector-
borne protozoan flagellates of the genus Leishmania in two subgenera L.
(Leishmania) and L. (Viannia). Visceral leishmaniasis, also known as “Kala-
azar” (KA), is usually caused by members of the L. donovani complex (L.
donovani (syn. L. archibaldi) in S. Asia and E. Africa, and L. infantum (syn.
L. chagasi) in C. and S. America, Mediterranean countries, C. Asia and parts
of China) (Lukes et al., 2007). There are also rare reports of VL caused by
infection with L. mexicana and L. tropica, which otherwise cause cutaneous
leishmaniasis (Sacks et al., 1995; Barral et al., 1986).
Leishmania are transmitted by blood-feeding females of at least 30 Phle-
botomine sandfly species in zoonotic transmission cycles involving one or
more mammal reservoir host, with the exception of two species (L. donovani
and L. tropica) that are transmitted in anthroponotic cycles. Domestic dogs
are the sole proven animal reservoir of VL due to L. infantum; however proven
transmission between sand fly vectors and wild hares (Lepus granatensis) in
Madrid, indicate their potential as secondary local reservoirs (Molina et al.,
2012). Despite a growing number of reports of L. donovani infections in dogs
and other mammals in E. Africa and on the ISC (Bhattarai et al., 2010;
Dereure et al., 2003; Alam et al., 2011; Sharma et al., 2009; Kenubih et al.,
2014; Kassahun et al., 2015; Siriwardana et al., 2012) these hosts have yet
to be shown to be epidemiologically relevant in maintaining transmission;
differentiating incidental or “sink” host from reservoir or “source” hosts is
required (reviewed by Quinnell and Courtenay (2009)).
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1.1. Disease in humans
1.1.1. The clinical spectrum
Leishmaniasis is characterised by a diversity of aetiological agents caus-
ing cutaneous (CL), mucosal (MCL) and visceral presentations dependent on
the species or strain of Leishmania and on the integrity of the host’s immune
system. Infections may last for months to years, requiring specific and varied
disease management strategies. VL is a systemic infection clinically charac-
terised by prolonged fever, weight loss, splenohepatomegaly, pancytopenia
and hypergammaglobulinaemia and anaemia. VL is almost always fatal if
not treated, amounting to 20,000-40,000 deaths per year (Alvar et al., 2012),
however the majority of VL-related deaths go unrecognised (Ahluwalia et al.,
2003; Barnett et al., 2005; Collin et al., 2006). The risk of mortality from
VL is exacerbated in the immunocompromised (e.g. HIV co-infections), pa-
tients with concomitant conditions (e.g. severe malnutrition) (Alvar et al.,
2008; Cerf et al., 1987; Anstead et al., 2001; Dye and Williams, 1993; Bern
et al., 2007), and those with limited treatment access due to conflict, famine
or population displacement (Reithinger et al., 2007). Even amongst patients
with access to VL treatment, the estimated case-fatality rate is 10% (Alvar
et al., 2012).
Post-kala-azar dermal leishmaniasis (PKDL) is the late and chronic de-
velopment of skin lesions, usually following the apparent clinical cure of VL
due to L. donovani in South Asia and Africa (Zijlstra et al., 2003). PKDL
can develop months to years following apparent successful treatment for KA,
or can develop without a previous KA episode. PKDL is not life threatening
but is associated with disfigurement and social stigma (see Section 1.1.2).
1.1.2. Natural history of VL disease
Transitioning from being susceptible to developing disease is a continuous
process, but one of the challenges of mathematical modelling involves defi-
nition of discrete stages (compartments) and their interactions and overlaps.
These stages are outlined below.
Susceptible. All na¨ıve individuals across all age groups are potentially
susceptible if exposed to Leishmania.
Individuals are not equally at risk of exposure and therefore infection,
with significant heterogeneities dependent on environmental and socio-economic
factors, especially related to poverty (Boelaert et al., 2009; Hasker et al.,
2012; Alvar et al., 2012). Once infected the following clinical categories are
recognised:
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Asymptomatic infection. The majority of infections are clinically
asymptomatic (subclinical) in the long term. There is no standard definition
of asymptomatic infection (Singh et al., 2014; Carneiro et al., 2011), though
infection is indicated by detection of anti-Leishmania antibody by immuno-
logical tests (e.g. rK39 immunochromatographic test, direct agglutination
test (DAT), enzyme-linked immunosorbent assay (ELISA)), by parasite de-
tection by tissue culture, or by PCR. The variation in the sensitivity and
specificity of these tests with respect to asymptomatic infection, hence their
usefulness for surveillance, is difficult to determine (Cunningham et al., 2012;
de Ruiter et al., 2014; Adams et al., 2013). Antibody presence for example
can indicate current infection, past exposure, or relatively recent cure post-
treatment for KA (see below). Thus, in a cross-sectional survey, individuals
that mount an effective immune response will include individuals who do not
progress to clinical KA.
With the exception of sporadic outbreaks (Ritmeijer et al., 2007), clinical
development of leishmaniasis is rare relative to the number of infections. The
ratio of infection to disease varies for L. infantum in Brazil (6.5:1, 9:1, 18.5:1),
Spain (50:1), Iran (13:1); L. donovani in Bangladesh (4:1), India and Nepal
(8.9:1), and L. donovani in Sudan (7:1,1.5:1), Kenya (6:1, 4:1), and Ethiopia
(5.6:1, 11:1) (Evans et al., 1992; Badaro et al., 1986b,a; Ali and Ashford,
1994; Schaefer et al., 1995; Zijlstra et al., 1994; Hailu et al., 2009; Davies
and Mazloumi Gavgani, 1999). Chapman et al. (2015) estimate that 20%
of asymptomatic infections develop into KA in Bangladesh, which is higher
than other estimates, but utilises individual, longitudinal data over 3 years.
The collective figures suggest that a larger proportion of L. donovani than L.
infantum asymptomatic infections progress to disease but some of the differ-
ences between species and studies come from different definitions of asymp-
tomatic infection and the use of different diagnostic tests; some studies use
the Leishmania skin test (LST) as a marker of infection; othes use antibody
detection tests of variable sensitivity and specificity. LST positivity is consid-
ered indicative of delayed-type hypersensitivity associated with a protective
T-cell mediated response, whereas anti-Leishmania antibody is not consid-
ered protective. Immune markers characterising likely progression to disease
are not fully defined but are influenced by host genetic factors, and the de-
gree of T-cell mediated response (reviewed by Kedzierski and Evans (2014)).
Well established risk factors influencing the probability of disease develop-
ment include malnutrition, HIV co-infection, and poverty-related conditions
(Bern et al., 2010; Boelaert et al., 2009; Alvar et al., 2008). Seroconversion or
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high Leishmania antibody titres indicate likely disease development, though
are not specific markers (Hailu et al., 2009; Hasker et al., 2014; Sudarshan
et al., 2014; Carneiro et al., 2011; Badaro et al., 1986a; Chapman et al.,
2015). Additional challenges in defining asymptomatic status are discussed
elsewhere (Singh et al., 2014; Carneiro et al., 2011).
Estimates of the pre-patent period, from detection of asymptomatic infec-
tion to development of KA varies between studies: in Sudan KA develops in
2-4 months (range: 2 weeks to 12 months) (Mueller et al., 2012); in Ethiopia
this period is typically 3-8 months (Hailu et al., 2009); in Brazil, a mean 4.9
months (SD 3.6 months) (Badaro et al., 1986a), and on the ISC 3-6 months
(Topno et al., 2010) and 142 days (Chapman et al., 2015).
Disease 1 - KA is defined on presentation of clinical signs, confirmed
by a positive serological or/and parasitological assay. In ISC operational
programmes, occurrence of at least 2 weeks fever and a positive rK39 test
result triggers treatment. The interactions between exposure and disease can
be inferred from the age distributions of KA cases. KA due to L. infantum
(also known as “infantile VL”) typically affects children <10 years (Badaro
et al., 1986a; Davies and Mazloumi Gavgani, 1999), whereas KA due to L.
donovani tends to be in older children and young adults <30 years in some
locations, or older in others (Hailu et al., 2009; Mueller et al., 2012; Burza
et al., 2014; Hasker et al., 2013). The age distribution will depend upon the
exposure history of the population and will likely vary over the course of an
epidemic cycle which is thought to be about 10-15 years on the ISC (Dye
and Wolpert, 1988).
Disease 2 - PKDL occurs as a sequel to treatment and apparent cure
of KA caused by L. donovani; it is clinically characterised as dermal mac-
ular, maculopapular, or nodular lesions on the face, upper arms and trunk
(Zijlstra et al., 2003). People are usually otherwise well and the symptoms
are less severe and distinct from KA with no associated mortality. Labora-
tory diagnosis of PKDL is challenging (Adams et al., 2013), and most cases
are diagnosed on clinical grounds. PKDL is more common, less chronic and
faster to develop the initial signs in parts of E. Africa than on the ISC: up
to 56% of treated KA patients develop PKDL within 6 months (range: 0-
13 months) in Sudan (Zijlstra et al., 2003; Musa et al., 2013), compared to
2-18% within 2-3 years (range: 6 months to 32 years) on the ISC (Rahman
et al., 2010; Singh et al., 2012; Uranw et al., 2011; Mondal et al., 2010a;
Sultana et al., 2012). In Sudan, skin lesions tend to heal spontaneously in
around 85% of patients and within 12 months, lasting a mean 9.7 months
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(SD 4.7 months; range: 2-28 months). In Bangladesh, around 50% (48/98)
of untreated PKDL patients showed spontaneous resolution within a median
19 months (Islam et al., 2013). Sudanese patients with lesions persisting >12
months show high anti-Leishmania antibody titres (DAT) and negative LST
(Zijlstra et al., 2003; Musa et al., 2002). For 5-10% of PKDL cases, there is
no prior history of KA, and occasionally PKDL presents concomitant with
KA (Zijlstra et al., 2003; Rahman et al., 2010; Islam et al., 2013). PKDL
in Bangladeshi KA patients is more likely in younger (<15 years) than older
patients; with a median PKDL patient age of 12 years (Islam et al., 2013).
Infectious. For individuals to be confirmed as infectious/infective it is
necessary to demonstrate their ability to infect the blood-feeding sandfly vec-
tor, which is known as xenodiagnosis. The infectious status of KA, PKDL
and asymptomatic patients is unclear, representing a large gap in our current
understanding of transmission pathways (see Section 1.1.3). A proportion of
symptomatic L. infantum infections are infectious to sandflies, but their de-
gree of infectiousness appears to be lower than for symptomatic L. donovani
infections and PKDL (Quinnell and Courtenay, 2009). The higher infec-
tiousness of HIV-co-infected individuals (Molina et al., 2003) suggests that
this condition could become locally more relevant particularly where HIV-
co-infection case numbers are rising (Alvar et al., 2008, 2012). KA patients
are usually treated soon after presentation at health facilities, so their period
of potential infectiousness depends on care-seeking behaviour and diagnostic
delays. However, relapses after treatment are not uncommon, which could
lengthen the infectious period. The proportion of the population develop-
ing PKDL, though smaller, may delay seeking health care especially when
symptoms are mild; also treatment may not be completed, for example if
considered by patients too expensive or logistically difficult (Ozaki et al.,
2011). In Bangladesh, current treatment guidelines call for a 120-day course
of intramuscular injections of sodium stibogluconate (SSG) (Rahman et al.,
2010). Thus a proportion of PKDL cases may remain in a chronic state and
are potentially infectious for long periods.
Recovered and Immune. KA rarely occurs more than once in an indi-
vidual, and treated cases appear to develop a strong immunity to disease (if
not infection). However, it is not clear whether asymptomatic infection (that
does not progress to disease) is protective against future infections and future
disease. The LST is often used as a measure of the protective immunity and
shows a variable duration. 98% (42/43) of subjects were still LST positive 10
years post-cure from L. infantum in Maranha˜o, Brazil (Viana et al., 2011).
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In other regions of Brazil, only 4% and 16% were LST positive after 8–720
days and 4–9 years respectively post recovery from KA (Mayrink et al., 1971;
Badaro et al., 1986a). Reasons for shorter positive skin test durations are
likely to include absence of re-exposure to Leishmania to stimulate immu-
nity, failing host immunity with age, and the technical quality and specificity
of heterologous vs homologous LST antigens (Bern et al., 2006). Few to no
new KA episodes have been reported amongst LST positives, and subsequent
episodes are rare in others truly cured of KA (Burza et al., 2014; Hailu et al.,
2009). Nonetheless, after clinical recovery, Leishmania antibodies persist for
variable periods of up to 12 years (Gidwani et al., 2011; Bern et al., 2005),
the variability partially determined by the degree of continued exposure and
any persistent infection.
On the other hand, relapses in response to less optimal treatment regimes
are not uncommon (see Section 1.4.1). To determine if immuno-competent
past cases return to be partially or fully susceptible to infection and disease,
it is essential to distinguish new infections from parasitological relapse, which
is rarely studied. Relapse has been observed in 119/8,409 immuno-competent
KA cases in a median 10.1 months (IQR: 7.1-13.8 months) with 32% of these
relapsing >12 months post-successful treatment with 20mg/kg Ambisome,
which is considered the current most effective treatment against KA on the
ISC (Burza et al., 2014). Longitudinal follow-up studies are few and current
parasite diagnostic tools may lack the required sensitivity to detect low-level
residual infections.
1.1.3. Transmission: xenodiagnosis vs tissue and blood parasite loads
Since most VL infections are asymptomatic, quantifying their transmis-
sion potential relative to KA and PKDL cases is critical. Assuming that
asymptomatically infected, KA and PKDL cases all contribute towards in-
fection in sandflies, it is possible that transmission is primarily driven by
the asymptomatic group, even if the relative infectivity of asymptomatics is
much lower than KA or PKDL (see Section 2.1). PKDL patients have also
been suggested to be an important reservoir based on observations that they
consistently harbour L. donovani parasites in skin lesions, often do not seek
or comply with long treatments, and can remain unsuccessfully treated for
years (Nasreen et al., 2012; Verma et al., 2010; Thakur and Kumar, 1992).
Cryptic reservoirs will become increasingly important to tackle as elimination
is approached.
Quantifying infectiousness of host populations relies on xenodiagnosis or
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artificial exposure of sandfly vectors to host blood, but xenodiagnosis stud-
ies in particular are difficult on logistic grounds (e.g. maintaining sand-
fly colonies) and ethical grounds (e.g. exposing asymptomatic infecteds).
Consequently xenodiagnosis studies are few, most are cross-sectional, and
involve small numbers of hosts or vectors (reviewed by Quinnell and Courte-
nay (2009)). Historical xenodiagnosis studies demonstrate that both KA
and PKDL patients can be infectious to sandflies: 18/21 L. donovani KA
patients, and 4/4 PKDL (nodular lesions) infected 2-42% and 15-53% of ex-
posed P. argentipes respectively, and 23/50 L. infantum KA patients were
infectious, on average, to 10-51% of exposed Lu. longipalpis / P. perniciosus
sandflies (reviewed by Quinnell and Courtenay (2009)). In contrast, 0/27
asymptomatic L. infantum infected individuals exposed to Lu. longipalpis
were infectious (Costa et al., 2000), but being LST positive, it is likely that
they had resolved their infections and were more appropriately classified as
recovered.
Molecular methods, particularly quantitative PCR (qPCR) to measure
parasite burdens in skin and peripheral blood, i.e. accessible to blood-feeding
sandflies, is more frequently being applied in population studies, and is often
assumed to be a reliable marker of transmission potential. Unfortunately,
the relationship between parasite load and xenodiagnosis outcomes are not
well defined, and are likely to vary with the Leishmania-host interaction,
clinical stage and kinetics of parasite tropism. It can be difficult to compare
studies as the number of target gene copies (e.g. kDNA for preparing qPCR
standards) varies between amastigotes and promastigotes, and even between
strains (Weirather et al., 2011). Studies suggest that there exists a parasite
density threshold above which canine and human infections are dispropor-
tionately infectious (Courtenay et al., 2014; Miller et al., 2014). In contrast,
natural wildlife hosts (e.g. foxes and hares for L. infantum, rodents for L.
braziliensis and L. tropica), in which infection is usually asymptomatic, show
no apparent relationship between parasite loads and infectivity to sandflies
(Courtenay et al., 2002a; Svobodova et al., 2003; Kassahun et al., 2015; An-
drade et al., 2015; Molina et al., 2012).
Leishmania burdens in blood may, to some extent, differentiate asymp-
tomatic and symptomatic infections and identify which infections are more
likely to progress to disease, or to relapse post treatment (Sudarshan et al.,
2014; Mary et al., 2006). L. infantum (Pourabbas et al., 2013; Mary et al.,
2006; Moral et al., 2002; Biglino et al., 2010), and L. donovani (Miller et al.,
2014; Sudarshan and Sundar, 2014) have been detected in blood in up to
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58% of asymptomatic infections by a cross-sectional study. 14% of 4,695
asymptomatic Ethiopians were qPCR-positive in blood of which 3.2% had
high genome equivalent counts (Miller et al., 2014), suggesting that distri-
bution of parasitaemias is skewed and that perhaps the small proportion of
asymptomatic infections with higher parasitaemia are more likely to develop
disease and have a disproportional role in onward transmission. However
of 44 Brazilian children with positive qPCR results at baseline, only 10 re-
mained qPCR-positive 12 months later, showing a significant decrease in
genome counts (dos Santos Marques et al., 2012). Only 4 of 25 asymp-
tomatic PCR-positive individuals remained PCR-positive 12 months later in
SE Brazil (de Gouvea Viana et al., 2008). In sharp contrast, 83% (80/97)
of asymptomatic individuals living in an active transmission region of Brazil
tested PCR-positive during 6 years follow-up (tested three times by PCR)
(Carneiro et al., 2011).
In PKDL patients, parasite loads are reported to be greater in nodular
compared to macular or papular lesions (Nasreen et al., 2012; Verma et al.,
2010, 2013), whereas samples from asymptomatic skin from PKDL patients
in Bangladesh (n=20) tested negative compared to the 95% positivity of
active lesions (Nasreen et al., 2012). PCR positive results were obtained
in 35% (8/23) of slit skin samples taken from PKDL lesions in the same
region (Islam et al., 2013). Any contribution of PKDL to onward transmis-
sion may differ substantially between Africa and the ISC due to differences
in PKDL onset, progression and clinical aspects as described above (Sec-
tion 1.1.2). Lesion type (i.e. parasite loads), treatment (see Section 1.4.1)
and healthcare-seeking behaviours are also likely to influence infectious du-
ration. Assuming non-biased selection of study subjects, the majority [77%
(106/138) and 97% (107/110)] of PKDL patients’ cutaneous lesions involved
macules and papules, and only 3% (3/110 patients) and 4% (5/138 patients)
were nodular forms; the remainder were mixed or complex lesion types (Nas-
reen et al., 2012; Islam et al., 2013). Also higher loads were recorded in
more chronic PKDL cases (>3 years history) compared to acute (<3 years
history) PKDL cases suggesting an increased parasite load with disease du-
ration (Verma et al., 2010).
1.2. Disease in dogs
L. infantum infection in the domestic dog also causes a spectrum of clini-
cal disease, from asymptomatic infection to severe, fatal disease (reviewed by
Solano-Gallego et al. (2009)). The burden of disease due to zoonotic visceral
11
leishmaniasis (ZVL) in dogs is difficult to quantify, since prevalence varies at
both large and small geographical scales, and diagnostic tests have varying
sensitivity and specificity. In Western Europe a review of canine serological
surveys found the overall seroprevalence in 500,000 sampled dogs to be 23%,
with a median value of 10% (Franco et al., 2011). The prevalence of disease
will be lower, but the true prevalence of infection will be much higher, since
serology is known to have low sensitivity for detecting asymptomatic infec-
tion (Baneth et al., 2008). The use of molecular methods has shown that
the real prevalence of infection can be up to 80%, in areas where <30% were
seropositive (Solano-Gallego et al., 2001; Lachaud et al., 2002). Similarly,
longitudinal studies using multiple diagnostic methods have shown that the
incidence of infection can be very high, with a mean time to infection of 115
days in one Brazilian study (Quinnell et al., 1997), and incidence of 40-92%
over the course of a transmission season in Europe (Dye et al., 1993; Oliva
et al., 2006). Indeed in some regions the incidence appears to be steadily
rising (Antoniou et al., 2009).
The course of infection is best examined using longitudinal studies of
natural infection. The few examples include a series of studies of kenneled
beagles exposed to natural infection in Italy, and a cohort study of owned
mixed-breed dogs in Amazon Brazil (Quinnell et al., 1997, 2001; Courtenay
et al., 2002b; Oliva et al., 2006; Foglia Manzillo et al., 2013). Such stud-
ies have confirmed that infected dogs can be qualitatively divided into two
groups: resistant and susceptible. In the Italian studies, around 50% of in-
fected dogs either showed no evidence of established infection but had low
levels of anti-leishmanial antibodies, or were PCR-positive with low or no
anti-leishmanial antibody response, and did not progress to clinical disease.
The other 50% of dogs, after a variable period of asymptomatic infection,
showed progressive infection, with increasing parasite burdens and serolog-
ical titres and development of clinical signs (Gradoni, 2015). Clinical signs
in canine VL are varied and non-specific: the most common signs are weight
loss, lymphadenopathy and a range of cutaneous signs (Baneth et al., 2008;
Foglia Manzillo et al., 2013). The proportion of dogs that develop clinical
disease is harder to estimate in Brazil, since dogs in many endemic areas are
generally malnourished and suffer from a range of other infections presenting
similar clinical signs. Resistance and susceptibility is associated with dif-
ferences in cellular immune responses, but little is known about the factors
that underlie this variation in outcome between dogs (Baneth et al., 2008;
Solano-Gallego et al., 2009). Age, sex, nutrition and co-infection may play
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a role, but variation in outcome is seen in even well-nourished experimental
dogs. Host genetics are known to be important, even within pedigree breeds
(Quilez et al., 2012).
Few studies have examined infectiousness, but it is likely that all suscep-
tible dogs become infectious, to a greater or lesser degree. In the Brazilian
study, about half of infected dogs became infectious, an average of 3 months
after seroconversion, i.e. about 6 months after infection (Courtenay et al.,
2002b). This and other xenodiagnostic studies have shown that the propor-
tion of infectious dogs varies with clinical status and also geographical area.
Meta-analysis of 7 published studies showed that the proportion of polysymp-
tomatic dogs that are infectious is very high (0.80), but that a proportion
of asymptomatic dogs are also infectious (0.29) (Quinnell and Courtenay,
2009). The proportion of infectious dogs was higher in European than Latin
American studies (0.86 vs 0.45), which could indicate a greater susceptibility
of an Old World sandfly vector, Phlebotomus perniciosus, to infection com-
pared to the major New World vector, Lutzomyia longipalpis. However, it
remains unclear what the role of resistant dogs is in disease transmission.
Although some asymptomatic dogs are infectious, it is not possible to tell
from cross-sectional studies whether these dogs are susceptible dogs in the
early stages of infection, or resistant dogs. The Brazil cohort study suggested
that most asymptomatic infectious dogs did go on to develop disease, and
that truly resistant dogs have only a small role in transmission (Courtenay
et al., 2002b).
Indeed there is a high degree of heterogeneity between symptomatic dogs
in their level of infectiousness, with very different contributions to transmis-
sion. Of 42 infected dogs (18 infectious) in the Brazilian cohort study, 7 (17%)
highly infectious dogs were responsible for >80% of the transmission events
(Courtenay et al., 2002b), and other studies show that 15-44% of infected
dogs are responsible for >80% of transmission (Travi et al., 2001; Molina
et al., 1994). These results have been corroborated by studies of tissue par-
asite burdens across dogs, which show similarly high levels of heterogeneity
(Courtenay et al., 2014).
Diagnosis of infection in dogs has been reviewed in (Solano-Gallego et al.,
2009). PCR, particularly qPCR, is the most sensitive diagnostic technique,
and is usually the first test to be positive early after infection (Oliva et al.,
2006; Quinnell et al., 2001). Detecting infection in resistant asymptomatic
dogs is difficult, as a proportion of PCR-positive resistant dogs do not go on to
seroconvert, and antibody levels are low and vary through time. Susceptible
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dogs appear to all seroconvert, though the time taken for seroconversion can
vary considerably. Clinical signs are not sufficient for diagnosis due to their
low specificity. Distinguishing infectious from non-infectious dogs is also
difficult, though parasite burden assessed by qPCR may provide a useful
measure of the level of infectiousness (Courtenay et al., 2014).
In addition to dogs and humans, a number of both domestic and wild
mammals can be naturally infected with L. infantum (reviewed by Quinnell
and Courtenay (2009)). In general, there is as yet no strong evidence that
hosts other than the domestic dog are responsible for significant human in-
fection, but further studies, particularly xenodiagnostic studies, are needed.
Other domestic or sylvatic reservoirs have thus been ignored in modelling to
date. However, there is recent evidence that hares, rather than dogs, have
been responsible for a localised outbreak of several hundred human cases in
Madrid (Molina et al., 2012).
1.3. Sandfly biology
Sandflies are small biting flies of the family Psychodidae. Only adult fe-
males take blood meals, while both adult males and females feed on plant
sugars; larvae are terrestrial (see Killick-Kendrick (1999) for a review of sand-
fly biology). The vector of VL on the ISC is Phlebotomus argentipes, though
P. papatasi is suspected to be a secondary vector. In Sudan the main vec-
tor is P. orientalis, with other vector species occurring in Kenya and China
(Killick-Kendrick, 1999). The most widespread vector of ZVL in the New
World is Lutzomyia longipalpis, which is likely to be a complex of several
species, while other species (Lu. evansi and Lu. cruzi) may be important
locally (Lainson and Rangel, 2005; Quinnell and Courtenay, 2009). In the
Old World, there are at least a dozen sandfly vectors for L. infantum, with
P. perniciosus and P. ariasi the major vectors in the western Mediterranean
(Killick-Kendrick, 1999).
1.3.1. Life expectancy
Sandflies have a relatively long generation time, taking at least a month
to develop to adulthood (Killick-Kendrick, 1999). A key epidemiological
parameter is the adult life expectancy, since to transmit infection female
sandflies need to survive long enough to take at least two blood meals and
to allow parasites to develop to infectivity (the extrinsic incubation period).
The length of the gonotrophic cycle varies between species, being around 3
days in Lu. longipalpis, around a week for P. ariasi, 5 days for P. argentipes
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and 5-11 days for P. papatasi (Srinivasan and Panicker, 1992; Lainson et al.,
1977; Palit et al., 1990).
There have been few studies of the life expectancy of adult sandflies of any
species under natural conditions. Adult life expectancy can be approximated
from field measures of physiological age using the parous rate. The proportion
of parous flies (flies that have laid eggs) approximates the proportion of flies
that are older than 1 gonotrophic cycle. This method has been used to
estimate the life expectancy of P. ariasi in France as around 6 days, that
of Lu. longipalpis in Brazil as 2.4 days, and that of P. papatasi in India as
14 days (Dye et al., 1987, 1991; Srinivasan and Panicker, 1992). The parous
rate of Lu. evansi in Colombia was comparable to that of Lu. longipalpis
in Brazil (Travi et al., 1996), while that of Lu. longipalpis in Colombia was
higher (Ferro et al., 1995), suggesting an average life expectancy of up to a
week. Mark-release-recapture methods can also be used to directly estimate
life expectancy of sandflies, such as the L. braziliensis vector Lu. (Nyssomyia)
neivai (Casanova et al., 2009). However, for VL vectors their use has been
limited to studies of dispersal, which have shown incidentally that adult Lu.
longipalpis can survive for up to 7-8 days (Dye et al., 1991; Morrison et al.,
1993a)), and P. ariasi for up to 28 days (Killick-Kendrick and Rioux, 2002).
1.3.2. Seasonality of sandflies
There is a pronounced seasonal variation in numbers of VL vectors, both
in the Old and New World. In tropical regions, sandflies are usually present in
every month, but with up to a 10-fold variation in sandfly numbers across the
year. On the ISC, numbers are lowest in December and January, when tem-
peratures are lowest, and typically highest in summer and the post-Monsoon
period; numbers correlate positively with temperature, but correlations with
rainfall are more variable (Ghosh et al., 1999; Picado et al., 2010a). In Ama-
zon Brazil, sandfly numbers peak at the end of the dry season, and this
variation in population size is reflected in a marked variation in the inci-
dence of canine infection across the year (Quinnell et al., 1997; Kelly et al.,
1997). The seasonal pattern in other areas of Brazil is different, with highest
numbers in the more arid NE Brazil typically occurring during or after the
rainy season (Sherlock, 1996; Deane and Deane, 1962), though some areas
show no clear seasonal pattern (Costa et al., 2013b). In the Mediterranean
area seasonality is more marked, with no adults present during the winter
months and sandflies surviving this period as larvae in diapause. In Italy the
period of sandfly activity runs from May to October/November, with highest
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sandfly numbers from June to August (Rossi et al., 2008). In mountainous
NW Iran, the VL transmission season lasts for the 4-5 month summer (), as
also observed in the Mediterranean (Gavgani et al., 2002). Seasonal patterns
are also often reflected in the parous rate, infection rate and other important
entomological parameters.
1.3.3. Feeding behaviour
The sandflies that transmit VL have fairly broad host choice. Lu. longi-
palpis will readily feed on a range of vertebrate hosts, and host choice is
determined largely by host size and accessibility (Quinnell et al., 1992; Mor-
rison et al., 1993b). Lu. longipalpis is not considered to be strongly anthro-
pophilic, though this may vary across its range, as members of the Lu. longi-
palpis species complex differ in their degree of attraction to human odours in
the laboratory (Rebollar-Tellez et al., 2006). In the Mediterranean, both P.
perniciosus and P. ariasi are similarly opportunistic feeders on mammalian
and avian hosts (Guy et al., 1984; de Colmenares et al., 1995). P. argentipes
and P. orientalis also feed on a range of mammals, both humans and do-
mestic animals, particularly cattle, buffalo and goats (Garlapati et al., 2012;
Gebresilassie et al., 2015; Palit et al., 2006)), though P. papatasi appears
to be predominantly anthropophilic (Palit et al., 2006). This lack of host
specificity means that domestic animals probably play an important role in
the epidemiology either as reservoirs and/or as sources of blood. On the
ISC, large numbers of sandflies are found peridomestically in cattle sheds,
while in Brazil, large numbers are often found in animal shelters such as
chicken sheds. Since neither cattle nor chickens are hosts of Leishmania, this
raises the possibility that domestic animals may reduce the infection rate
in humans by diverting sandflies from humans or dogs and lowering both
the feeding and infection rate (zooprophylaxis) (Alexander et al., 2002; Bern
et al., 2010). These effects could be magnified since both Lu. longipalpis and
P. argentipes are thought to have a lek-based mating system, where males
aggregate on hosts and attract females using pheromones (Dye et al., 1991;
Lane et al., 1990). Conversely, the presence of domestic animals could in-
crease the biting rate by acting as a maintenance host for the vector and thus
increasing vector numbers (Alexander et al., 2002; Bern et al., 2010) (zoopo-
tentiation); both positive and negative associations between cattle and risk
of infection have been reported on the ISC (Bern et al., 2010).
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1.4. Control of human VL
1.4.1. Treatment of VL
The pentavalent antimonials (sodium stibogluconate [SSG] and meglu-
mine antimoniate), the mainstay treatment for VL since the 1940s, are gen-
erally effective, with the notable exception of parts of South Asia where
up to 60% treatment failure in Bihar, India (Mondal et al., 2010b; Sundar,
2001; Sundar et al., 2000) and neighbouring Nepal (Rijal et al., 2007, 2003)
have been reported and associated with parasite resistance (Lira et al., 1999;
Downing et al., 2011). Antimony treatment requires 30 day hospitalisation
for daily injections imposing a catastrophic economic burden on affected
families (Ozaki et al., 2011). Antimony is highly toxic, particularly in mal-
nourished and very young or old patients, hence diagnostic test specificity
is of particular importance. In the past two decades of drug development
(reviewed by den Boer et al. (2009)), conventional forms of amphotericin
B, liposomal preparations of amphotericin B, miltefosine (MIL), and paro-
momycin have been registered in various countries to treat VL. Conventional
amphotericin B has replaced antimonials as the first-line treatment for VL in
parts of India (Olliaro et al., 2005), following trials showing that it is highly
effective and safe (Sundar et al., 2003, 2004).
Paromomycin (PM) (formerly known as aminosidine), is an aminogly-
coside antibiotic with good anti-leishmanial activity, showing high levels of
efficacy and safety, and low relative cost, and was registered in India in 2006.
MIL is the only oral drug against VL registered for use in India since 2002
and has been adopted by the Indian Ministry of Health in parts of Bihar
(Matlashewski et al., 2011) and more recently in Nepal. However it requires
28 days of oral treatment, and as it is teratogenic it cannot be used to treat
pregnant or lactating women, which hinders its use in roll-out programmes.
Reported treatment failure rates in immunocompetent patients are up to 21%
(and 33% amongst children) within 12 months in Nepal and 5-10% within
6 months in India, the former attributed to a low-dose-response drug ex-
posure rather than in vitro parasite resistance (Dorlo et al., 2014; Sundar
et al., 2012; Rijal et al., 2013). The 2005 Memorandum of Understanding
for a “VL Elimination Programme” on the ISC was partially based on re-
placement of antimony by MIL as the first-line treatment (Mondal et al.,
2009). Single-dose liposomal amphotericin B (AmBisomer) showing signifi-
cantly diminished renal toxicity, is now considered the best available therapy
against L. donovani on the ISC (WHO, 2010a), at a negotiated affordable
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price (Matlashewski et al., 2011; de Melo and Fortaleza, 2013), and has re-
cently been adopted in some regions of the ISC (Burza et al., 2014).
In E. Africa, monotherapies have proven less efficacious and with greater
regional variability than seen in S. Asia (den Boer et al., 2009; Mueller et al.,
2007; Khalil et al., 2014). Since AmBisomer requires a cold chain and is
very expensive with limited availability, it is considered a second line treat-
ment, but under continued evaluation (Khalil et al., 2014). One concern with
monotherapies is the potential development of parasite resistance, particu-
larly MIL and PM, because they require long treatment courses, lowering
compliance. MIL resistance is reported to result from a single point muta-
tion in the MIL transporter at the Leishmania plasma membrane, associated
with reduced accumulation of cell reactive oxygen which causes apoptotic
death (Seifert et al., 2007; Das et al., 2013). Parasite resistance against
amphotericin B is thought to be less likely (Lachaud et al., 2009). The
safety, tolerance and effectiveness of combination therapies (reviewed by van
Griensven et al. (2010)) now trialled in India and E. Africa (see also Musa
et al. (2012); Sundar et al. (2008); Chunge et al. (1990); Thakur et al. (2000);
Melaku et al. (2007); Seaman et al. (1993)) are encouraging, and expected
to help slow the rate of parasite resistance to treatment, to reduce treat-
ment duration, to enhance compliance, and to be cost-effective (Musa et al.,
2012; Hamad et al., 2010; Croft et al., 2006). Following further efficacy trials
(Khalil et al., 2014; Musa et al., 2012), WHO recommended 17-day treatment
with PM combined with SSG as a first line treatment against VL in E. Africa
(Khalil et al., 2014). In Brazil, amphotericin B and liposomal amphotericin
B are currently recommended by the Ministry of Health with multicentre
clinical trials underway (de Melo and Fortaleza, 2013). However, no cur-
rent or proposed treatment would be suitable for mass drug administration,
which emphasises the importance of parallel development of accurate and
operational diagnostics.
1.4.2. Parasite loads in response to treatment
In relation to transmission, the choice of an appropriate VL treatment
regime to ensure parasite clearance and to eliminate potential infectivity to
sandflies is essential. Leishmania burdens in treated VL patients generally
decline during treatment (reviewed by Kip et al., 2014; see also Pourabbas
et al., 2013; Moura˜o et al., 2014; Mary et al., 2004, 2006; Aoun et al., 2009;
Sudarshan et al., 2011). However inadequate drugs, doses and durations may
result in parasite persistence (e.g. <50% and <60% tissue parasite clearance
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respectively immediately after, and 6 months after, completion of low dose
PM treatment in Sudan (Hailu et al., 2010)). Relapses with a resulting rise in
parasite loads are not uncommon (e.g. Pourabbas et al. (2013); Moura˜o et al.
(2014)), and even in KA patients considered clinically cured without recorded
relapse, residual parasites may persist e.g. in 11/21 Iranian patients treated
with antimony (Glucantime) Pourabbas et al., 2013; 2/6 patients treated with
SAG (Verma et al., 2010), and 4/48 Brazil children under various treatment
regimes (Moura˜o et al., 2014).
1.4.3. Vector control
Indoor Residual Spraying (IRS)
Vector control by IRS using DDT or pyrethroid insecticides is a key com-
ponent of national VL control campaigns, with mixed success in reducing
infection incidence via purposeful IRS against Leishmania vectors, or as a
benefit of the spraying campaigns against malaria vectors (Alexander and
Maroli, 2003; Ostyn et al., 2008). IRS is effective against adult vectors
that blood-feed indoors (endophagic) or rest indoors between blood-feeding
and searching for an oviposition site (endophilic). IRS is not expected to
impact on exophilic and exophagic vectors, nor immature stages; though
sandfly breeding sites are largely unknown (Alexander and Maroli, 2003).
Measurable entomological indicators of control success include reductions in
human landing rates, blood-feeding success, or human blood index, and re-
duced vector survival (lower parous rates), as demonstrated for a wide range
of New World (Davies et al., 2000; Feliciangeli et al., 2003a,b; Courtenay
et al., 2007; Falcao et al., 1991), and Old World sandfly species (Benzer-
roung et al., 1992; Reyburn et al., 2000; Joshi and Rai, 1994; Kaul et al.,
1994; Mukhopadhyay et al., 1996; Joshi et al., 2009). Insecticide deterrency
(sometimes called repellency cf. excito-repellency) induces vectors to avoid
contact with insecticide-treated surfaces, thus potentially diverting infectious
bites onto unprotected hosts; however this is not a usual feature of current
insecticide products for vector control.
The only research-based cluster randomised trial to evaluate IRS was
conducted in India, Bangladesh and Nepal, though interventions varied in
insecticides used (DDT in India, deltamethrin in Bangladesh, and alpha-
cypermethrin in Nepal) and in the wall surfaces treated (Joshi et al., 2009).
House and cattle shed spraying reduced the indoor P. argentipes overall den-
sity by 72%, an effect consistent across sites, though with mixed results
reported in other studies in India (Kumar et al., 2009; Picado et al., 2010b;
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Dinesh et al., 2008a). Since 1991-2, the Indian Kala-azar Control Program
has promoted two IRS interventions per year using DDT; in Nepal IRS op-
erational programmes use predominantly lambda-cyhalothrin (Joshi et al.,
2003), whereas in Bangladesh IRS was very sporadic to non-existent up to
2010 (Bern and Chowdhury, 2006; Mondal et al., 2008). In Brazil, reactive
IRS using lambda-cyhalothrin, cypermethrin or deltamethrin is conducted on
detection of a KA case (da Sau´de Secretaria de Vigilaˆncia em Sau´de Departa-
mento de Vigilaˆncia Epidemiolo´gica, 2006). IRS government-run campaigns
against VL vectors appear to be absent in E. Africa.
Despite some encouraging entomological research outcomes, IRS as de-
ployed under the umbrella of operational VL control programmes has had
little to no impact on VL incidence, either in India (Picado et al., 2012; Ostyn
et al., 2008), Nepal (Joshi et al., 2006), Bangladesh (2006) or Brazil (de Souza
et al., 2008). However robust IRS evaluation studies are limited (Quinnell
et al., 2001; Picado et al., 2012), though guidelines to monitor IRS in the
context of the VL elimination programme are now in place (WHO, 2010b).
In India, resistance of P. argentipes to DDT and pyrethroids is patchy (Ostyn
et al., 2008; Dinesh et al., 2008b). The Indian and Nepalese routine IRS ac-
tivities are considered suboptimal due to financial and logistical constraints,
poor quality spraying practices and low community compliance (Chowdhury
et al., 2011; Picado et al., 2012; Coleman et al., 2015). In Brazil, spray-
ing lambda-cyhalothrin in animals sheds where the vector Lu. longipalpis
congregates was shown to increase the numbers of Lu. longipalpis in house-
hold dining huts (attached to houses), indicating the importance of complete
coverage (Kelly et al., 1997).
Insecticide-impregnated nets and materials
Insecticide-treated nets (ITNs) treated with synthetic pyrethroids have been
shown to be effective against mosquito vectors and malaria incidence (Lengeler,
2004). ITNs against many species of sandflies similarly demonstrate knock-
down and toxicity (reviewed by Alexander and Maroli (2003); Ostyn et al.
(2008)), and have been shown to be efficacious in reducing the incidence of
both anthroponotic CL and zoonotic CL (Jalouk et al., 2007; Alten et al.,
2003; Reyburn et al., 2000; Moosa-Kazemi et al., 2007; Davies et al., 2000;
Kroeger et al., 2002; Yaghoobi-Ershadi et al., 2006; Tayeh et al., 1997).
In eastern Sudan, lambda-cyhalothrin impregnated bednets against the
vector P. orientalis reduced the incidence of KA to 1.6% in a single inter-
vention village compared to 12.4% in the control village, but lacked repli-
cation (Elnaiem, 1996). Provision of deltamethrin impregnated bednets to
20
114 follow-up Sudanese villages in response to the 1999-2001 VL epidemic,
reduced VL by 59%; the greatest impact was reported to be 17-20 months
after the distribution of the nets (Ritmeijer et al., 2007). An intervention
trial against P. argentipes in Bangladesh indicated that widespread bednet
impregnation with slow-release insecticide may reduce the frequency of VL,
however the study was inconclusive because it was not randomised and lacked
sufficient replicates (Mondal et al., 2013).
Whilst few ITN trials have been conducted against VL vectors, a notable
exception is the cluster randomised controlled trial known as the “Kalanet
Trial” (www.kalanet.info) which distributed deltamethrin impregnated long-
lasting bednets to 26 paired intervention and control villages in highly en-
demic foci in India (16 pairs) and Nepal (10 pairs) (Picado et al., 2010b). The
control arm continued existing practices (irregular IRS, use of untreated nets,
and treatment of VL), which were accounted for in the final analyses. After 24
months follow-up, there was no significant reduction observed in seroconver-
sion in intervention (347/6372=5.4%) compared to control (345/6319=5.5%)
residents, or in the risk of developing KA (37/9829=0.38%) verses controls
(40/9981=0.40%). However the intervention did significantly reduce the risk
of malaria (RR= 0.46 [95% C.I. 0.28-0.77]). The authors suggest that possi-
ble reasons for the failure to impact on VL transmission are that P. argentipes
may be more exophilic (lives outdoors) and exophagic (feeds outdoors), and
zoophilic (prefers feeding on animals), than previously considered as the ef-
fect of the intervention on vector density was measured only indoors (Picado
et al., 2015). Thus the entomological impact of bednets on sandflies depends
largely on both host and vector behaviours (Courtenay et al., 2007); further
issues about feasibility are discussed elsewhere (Courtenay et al., 2007; Ostyn
et al., 2008; Picado et al., 2015).
High coverage with ITNs may result in reduced vector infection rates (i.e.
a mass effect) in anthroponotic cycles though this has not been empirically
demonstrated. The role of ITNs in combating zoonotic transmission is lim-
ited: for anthroponotic VL, ITNs are expected to provide personal protection
against infective bites, and theoretically to impact on the transmission cycle.
For zoonotic organisms (where humans are not reservoirs) ITNs will protect
and impact on indoor vectors, but are not expected to directly impact on the
transmission cycle.
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1.5. Control of ZVL
In areas where human cases are comparatively rare, such as the Mediter-
ranean region, ZVL is considered as a veterinary rather than a human public
health problem, and there are typically no national measures to control in-
fection. In other areas, such as Brazil, national ZVL programmes are in
place. In Brazil, the national control programme is focused on (i) detection
and culling of seropositive dogs, (ii) indoor residual spraying (IRS) of houses
and animal shelters and (iii) diagnosis and treatment of human cases. These
methods have been successfully used in China to control infection, although
the relative contributions of vector and dog control are not known (Zhi-Biao,
1989; Costa, 2011). In Brazil such measures have shown little or no effi-
cacy, as the number of human and canine cases have not declined. As a
result, the rationale for these methods, especially dog culling, has been in-
creasingly questioned on theoretical, practical and ethical grounds (Otranto
and Dantas-Torres, 2013; Dye, 1996; Costa, 2011; Courtenay et al., 2002b).
A number of logistical problems have been identified with the dog culling
programme: coverage is often low, the serological diagnostic tests used are
relatively insensitive, and there are long delays between sampling and culling
(reviewed by Quinnell and Courtenay (2009)). Culled dogs are also rapidly
replaced with na¨ıve, uninfected dogs (Nunes et al., 2008). These concerns
have been partly addressed by the recent introduction of a new rapid diag-
nostic test, which should reduce delays and may improve sensitivity. Unfor-
tunately, the efficacy of either IRS or dog culling remains unknown, due to a
lack of well-designed, large field trials (Romero and Boelaert, 2010; Quinnell
and Courtenay, 2009).
Other potential control methods include protection of dogs with topical
insecticides, protection of humans with bednets (see Section 1.4.3), pheromone
traps for sandflies, dog treatment, or canine vaccines. Synthetic pyrethroids
applied to dogs as topical formulations or in impregnated collars have been
shown to be highly effective in protecting dogs against sandflies, with ef-
fects lasting for up to 8 months for collars but only 3–4 weeks for topical
“pour-on” applications. Under field conditions, randomised controlled trials
have shown such methods to also be highly effective in protecting individ-
ual dogs against infection, with efficacies of 50-100% (reviewed by Quinnell
and Courtenay (2009); Otranto and Dantas-Torres (2013)). However, only
one randomised, community-level control trial against human infection has
been carried out, showing deltamethrin-impregnated collars fitted to dogs
in NW Iran to reduce canine infection by 53% reduction in canine infection
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and by 38% in humans (Gavgani et al., 2002). Lu. longipalpis males pro-
duce a pheromone that attracts females to lekking sites on hosts, and field
trials have shown that lures using synthetic pheromone are highly attractive
to both male and female sandflies, and could potentially be used in control
programmes (Bray et al., 2014).
Treatment of dogs with anti-parasitic drugs is widely used in a veterinary
context in Europe, but it is not used in control programmes. Indeed, treat-
ment of dogs with drugs used to combat human infection is banned in Brazil,
in order to reduce the possibility of drug resistance. The clinical response
of dogs to treatment varies according to the initial condition of the dog, but
clinical cure is often seen in dogs with mild to moderate infection (Solano-
Gallego et al., 2009). However, treatment does not result in parasitological
cure, and dogs are likely to remain infectious, though at a reduced level. In
contrast to drugs, canine vaccines may provide a very useful tool for disease
control, and much effort has been invested in the development of a canine
ZVL vaccine. Three vaccines are now commercially available: Leishmune
and Leish-Tec in Brazil, and CaniLeish in Europe. Relatively little has been
published on the efficacy of these vaccines, particularly from phase III field
trials, and a number of published studies have methodological issues (Wylie
et al., 2014). There is evidence from several studies that Leishmune is effec-
tive against clinical disease, and maybe also against infection, with reported
efficacies of 76-100% (Oliveira da Silva et al., 2001; Borja-Cabrera et al.,
2002; Nogueira et al., 2005; Felix de Lima et al., 2010). A single field study
of CaniLeish shows no significant effect on infection, but a 68% reduction
in the proportion of dogs with clinical disease (Oliva et al., 2014). There
have been no published phase III studies yet for Leish-Tec. An anti-disease
(as opposed to anti-infection) vaccine would be suitable, provided that the
vaccine reduced parasite loads to a level below that at which parasite trans-
mission occurs. It has also been suggested that Leishmune may have specific
transmission-blocking effects (Saraiva et al., 2006). Vaccines may also have
immunotherapeutic effects when given to already infected animals (Borja-
Cabrera et al., 2004).
2. Mathematical models of visceral leishmaniasis
The number of mathematical models of VL in either humans or animals
is low, in particular for VL on the Indian subcontinent (see Table 5) where
the majority of elimination efforts are currently being targeted. The exist-
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ing models are quite varied both in the biological details that they capture,
but also in their underlying mathematical structure, however it is noted that
they are mostly still ODE models which neglect spatial effects. As might be
expected with models of an NTD, many lack realistic parameterisation that
arises through model fitting to high-quality data. Several of the models do
address pertinent questions related to the control of disease through inter-
vention such as detection and treatment and vector control, but none directly
address the WHO goal of elimination of disease as a public health problem
by 2020 nor generate the likely time to full elimination given the current
prevalence of disease and existing/proposed control strategies. These exist-
ing models of VL pave the way for more sophisticated models of this disease
that utilise and extend prior frameworks.
The two forms of visceral leishmaniasis, caused by L. donovani and L. in-
fantum, are separated both geographically and by the way in which they are
modelled. L. donovani on the Indian subcontinent is considered to be anthro-
ponotic with only humans and sandflies playing a role in the transmission
cycle. Consequently models of KA on the ISC do not feature non-human
populations explicitly, although it is recognised that the presence and rel-
ative density of alternative hosts may ultimately affect the human biting
rate. ZVL (caused by L. infantum) primarily affects Brazil in addition to
the Mediterranean region and parts of the central Asia and China. In these
regions an animal population (dogs) not only forms part of the transmission
cycle, but it is also thought to drive it. In regions of East Africa affected by
L. donovani and on the ISC, other animals have been shown to be infected
though their contribution towards transmission remains untested.
2.1. Infection in humans
In order to understand the transmission dynamics of VL it is important
to be able to identify the natural progression of the disease in humans. From
this biological starting point, a mathematical model can be developed.
The first model of VL in humans by Dye and Wolpert (1988) was a simple
compartmental model in which individuals in the human population were
considered to be either susceptible to VL infection, infected (and infectious) or
have experienced the disease and were recovered and immune from reinfection.
This basic structure has been well studied for many diseases and is known as
an SIR progression model (see Figure 1) (Keeling and Rohani, 2008). Despite
its relative simplicity, such a model can be analysed easily and provides clues
towards understanding observed phenomena. For example, Dye and Wolpert
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were able to show that if VL is considered to have an immunising effect, this
alone could generate the pronounced inter-epidemic periods seen historically
(1880–1940) in India. Other factors such as treatment, disasters (including
earthquakes) and other diseases such as influenza governed the size, but not
timing of these epidemics.
Figure 1: Simple model of SIR VL progression in humans as used by Dye and Wolpert
(1988) with progression between stages at rates λH and φH . Here the red box denotes the
only infectious stage.
SH IH RH
λH γH
Although biological understanding of VL has advanced since 1988, it was
22 years after this original model that an improved dynamic transmission
model was developed to examine contemporary VL on the ISC. The model
by Mubayi et al. (2010) sought to quantify the underreporting bias of KA
cases in Bihar, India by combining a transmission model with data (from 2003
and 2005) from the most affected 21 of 38 districts in Bihar. In addition to
the SIR compartments, the model includes stages for: latent infection where
individuals have been infected with Leishmania but are not yet infectious to
sandflies; and treatment compartments where diseased patients attend either
public or private centres before recovery is possible (see Figure 2). This is a
type of SEIR (susceptible - exposed - infected - recovered) model. The pro-
portion of those attending public facilities is key to answering the amount
of under-reporting as only public health centres were required to report KA
cases. Within the model, any privately treated patients are assumed to be un-
reported. In 2006-2009 a retrospective study indicated that the proportion of
cases receiving treatment for VL in government health facilities was low (less
than 30% for adults, and as low as 13% for 5 to 10 year olds (Gidwani et al.,
2011)) indicating that there could be a large amount of under-reporting.
To include more realistic latent, infectious and treatment periods, Mubayi
et al. (2010) make use of the “linear-chain trick”, a mathematical technique
where each of these compartments is partitioned into subcompartments. Us-
ing this method generates Erlang-distributed (gamma-distributed with the
shape parameter, k ∈ N) periods rather than exponential distributed peri-
ods (MacDonald, 1978). The number of subcompartments is dictated by the
shape of the probability density function for that epidemiological period; for
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example, Mubayi et al used n = 16 compartments for the latent stage but
only m = 2 for the infectious stage because the variance was much higher for
duration of infectious period compared to the variance of latent period. Al-
though this methodology provides a useful mathematical tool for modelling
the variability in the latent and infectious periods, the subcompartments do
not correspond directly to biological processes.
Figure 2: Model of VL progression considered by Mubayi et al. (2010) including Erlang
distributed latent, infectious and treatment stages with red denoting the infective classes
and yellow, the treatment in either public or private health centres.
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Under this model the percentage of underreporting is 100(1 − p) where
p is the proportion of patients who attend public health centres. The mean
number of reported cases per month is the influx into the first disease com-
partment of the model assuming that all new cases are immediately reported
from public health centres but never from private ones:
reported cases = pmγHIm (1)
This equation may be rearranged to find p based on the endemic equilibrium
prevalence (denoted by stars):
p =
reported cases
mγHI∗m
where I∗m can be expressed as a function of model parameters.
Using this methodology it was found that there was on average 88%
underreporting of infection in 2003 which decreased to 71% in 2005. Under-
reporting reached as high as 96% (in Jahanabad district) and a positive cor-
relation was found between underreporting and population density (Mubayi
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et al., 2010). This modelling demonstrates the huge extent of underreporting
that has likely occurred in the past due to differences in reporting between
health facilities and shows that caution must be taken with standard reported
incidence.
These first two dynamic models of VL progression in humans were tailored
to address specific questions; the first regarding inter-epidemic periods and
the second addressing underreporting. However there are other aspects of
L. donovani infection which are absent from these models, most notably the
inclusion of asymptomatic infections and PKDL.
The first transmission model to include this disease state was by ELmo-
jtaba et al. (2010a) who modelled infection in Sudan; this model was later
extended (ELmojtaba et al., 2010b, 2012). The compartmental model was
a typical SIR-type model with an extra infected (and infectious) compart-
ment for PKDL patients (see Figure 3). In this framework, infected patients
who are treated either fully recover (with probability (1 − f)) or develop
PKDL (with probability f) following KA. The authors assumed that PKDL
was linked to effectiveness of treatment and so (1 − f) is proportional to
effectiveness. PKDL patients are assumed to be treated or to spontaneously
recover (with rate ηH) and once again become non-infectious.
Figure 3: Model of VL progression adopted by ELmojtaba et al. (2010a,b, 2012) with
both KA (IH) and PKDL (PH) classes and red denoting the infective classes. Following
KA, patients either develop PKDL with probability f or recover immediately.
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By creating this extra compartment, the authors were able to analyse the
effect of treatment for both KA and PKDL, including both rate and effec-
tiveness (this is discussed further in Section 4). As this model was developed
for the Sudan, it may be reasonable to model instantaneous transition from
KA infection to PKDL due to the relatively short time (0–6 months) between
the two, however, this can be amended to incorporate a dormancy period be-
tween the two symptomatic stages (see Figure 4) and would make the model
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structure more appropriate for the ISC where the onset of PKDL can be 3
years after KA treatment.
Figure 4: Model of VL progression with both KA (IH) and PKDL (PH) classes with inter-
mediate dormancy (DH). Red denotes the infective classes. The probability of progression
to PKDL from KA is the same as before (Figure 3), however the time from treatment to
PKDL onset is on average ξ−1.
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The dynamic model (and variants thereof) by Stauch et al. (2011, 2012,
2014) includes a dormancy period between KA and PKDL, however they also
add many more compartments to the human progression including classes for
first and second-line treatment and asymptomatic infection. Conceptually
the Stauch progression is not dissimilar to the approach illustrated in Figure
4, with an additional asymptomatic class occurring before KA symptoms,
possible spontaneous recovery from asymptomatic infection, and waning im-
munity from the recovered class to susceptible. These additions are shown
in Figure 5.
Figure 5: Model of VL progression with asymptomatic VL (AH), KA (IH) and PKDL
(PH) classes with intermediate dormancy (DH). Red denotes the infective classes.
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Using this model of disease progression, Stauch et al then create further
subcompartments which are tied to diagnostic test results, symptoms and
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Figure 6: Compartmental diagram showing VL progression paths in humans (adapted from
(Stauch et al., 2011)). Underneath their corresponding results for 3 different tests for VL
is shown (as given by Stauch et al. (2011, 2012, 2014)). Blue boxes denote individuals who
do not play a role in transmission of disease to the vector. The red boxes denote those
that do or might (with asymptomatics contributing much less (40- to 80-fold less) than
KA or PKDL patients.
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treatment. For example, asymptomatically infected people are now strati-
fied into two separate classes, denoted here by AH1 and AH2. The first of
these groups of people have positive PCR but negative DAT results, whereas
the second group test positive for both. KA patients also have PCR/DAT
positive tests, however the presence of symptoms is used to distinguish them
from asymptomatics, and the treatment they are receiving (no treatment,
first-line and second-line) assigns their subcompartment. Figure 6 shows how
the new compartments are amended from the assumed progression (Figure
5) and the results of diagnostic tests.
This model was developed from and fitted to cross-sectional data from the
Kalanet study in India and Nepal (see Section 1.4.3). The model does not
take account of the sensitivity or specificity of the three diagnostic tests used
in the trial. Unlike other models of VL, this model allows for waning immu-
nity, which is the loss of immunity to Leishmania infection over a period of
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time. Through fitting to the data, the average time spent immune (in the RH
compartment) was just 307 days, which is shorter than might be expected.
The model also included the impact of HIV co-infection upon the dynamics
of VL, with a greater proportion of infected people developing symptoms if
they were HIV-positive compared to HIV-negative. As co-infection of these
two pathogens was not part of the Kalanet study, the HIV prevalence had to
be taken from regional estimates.
Through tying human VL progression to results of diagnostic results,
Stauch et al have raised an important question: how should asymptomat-
ically infected individuals (who are PCR positive) be modelled within the
transmission cycle? Such people are infected with Leishmania parasites but
their role in infection of sandflies is uncertain (see Section 1.1.3). In the
model of Stauch et al “late stage” asymptomatic were assumed to have a
reduced infectivity by some factor, called here ε, compared to symptomat-
ically infected, KA individuals (who have infectivity pV towards sandflies).
“Early stage” asymptomatic were assumed to have even lower infectivity of
0.5ε, although the justification for this is not clear. Through model fitting
the reduced infectivity parameter, ε, was estimated to be 1/40 and so this
would indicate that asymptomatics are 40 to 80-fold less infectious than KA
or PKDL patients.
The model results suggest that even at this low infectivity, asymptomatic
individuals are a large enough group to sustain transmission and, therefore,
that treating KA and PKDL patients, alone is unlikely to be sufficient to
reduce transmission enough to achieve elimination as a public health prob-
lem. This is the only dynamic model to examine asymptomatically infected
humans. It points towards a need to fit models that include asymptomatic
individuals to other data sets, but also emphasises the need for xenodiagnos-
tics. Ultimately, even if the individual infectivity of asymptomatics is low,
this should not be dismissed, as if there are many such individuals, it may
hamper intervention efforts.
Chapman et al. (2015) took an alternate approach to previous modellers
to infer both rates of disease progression and durations of disease states by
developing a multistage Markov model of the natural history of VL infection.
Utilising data from a longitudinal study in Fulbaria upazila of Bangladesh,
they concluded that disease durations were longer than those estimated by
Stauch et al including a waning immunity of 1110 days (988–1247 95% CI).
Chapman et al. (2015) also found that progression from asymptomatic infec-
tion to KA was high (14.7%) compared to Stauch et al (0.33%).
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Given these long duration estimates and high rates of progression to KA,
it would be expected that a dynamic transmission model similar to that
of Stauch et al may produce different results when parameterised with the
updated values. In particular, asymptomatics may not be responsible for
maintenance of transmission as found by Stauch et al. (2011), however as
asymptomatic infection is found to progress more often to KA, understanding
the dynamics of this subclinical, infected class of individuals will remain
important.
Figure 7: Uncertainties in the human infectious reservoir. Here all individuals who may
contribute towards infection in the vector are shown in the large red box. “Infectious”,
ID individuals are always assumed to be infective to sandflies and “dormant”, DH (before
relapsing to PKDL) are thought to never be infective but do still have low parasitaemia.
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SV IV
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Different models have made very different assumptions both about disease
progression and parameterisation. The huge variability in parameters and
their values may be attributed both to the underlying model structures and
also the uncertainty in many factors in transmission and progression, such
as rates or probabilities, which are either hard to measure or vary greatly by
region. Consequently this will impact on the cross applicability of results.
The mathematical modelling of L. infantum infection in humans is lim-
ited to SIR-type models, where people are only considered to be “spill-over”
hosts from a main transmission cycle between sandflies and dogs. As PKDL
does not occur for this species of parasite, this human disease progression
is a reasonable assumption. In many endemic settings where L. infantum is
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found, the prevalence in dogs is much greater than in humans, and so little
transmission is assumed to occur from humans.
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Table 1: Parameters associated with human VL progression and their notation used here and across modelling papers. All
rates are per capita unless stated otherwise.
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rate of becoming symptomatic σH - - γh* γHP + fHSγHD
probability of PKDL after KA f - (1− σ) - p2 + p1p4**
rate of developing PKDL after recovery ξH - - - δHL
disease-induced mortality δH d δ - µK
waning immunity ωH - - - ρHC
treatment rate (1st) γH - α1 αh* τ1
treatment rate (2nd) - - - - τ2
treatment rate (PKDL) ηH - β
† - τ3
probability of non-private treatment p - - p -
(1st) treatment-induced mortality - - - - µT1
(2nd) treatment-induced mortality - - - - µT2
*=Erlang distributed
**=either with or without second treatment and conditional upon survival
†=spontaneous PKDL recovery is given at a rate α2
‡=c is the vectorial capacity; see Section 2.3 for this derivation
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2.2. Infection in dogs
Some models take a standard SI (Mejhed et al., 2009), SEI (Salah et al.,
1994; Reithinger et al., 2004) or SEIR (Ribas et al., 2013) compartmental
progression for dogs, however the first model of VL in dogs (Dye, 1988) takes
the approach where some dogs have an innate resistance which is fixed at
birth. These dogs, which will be referred to here as ”never-infectious” (to
use terminology coined later by Courtenay et al. (2002b)), play no role in the
transmission cycle (see Figure 8). This approach is also taken by Dye (1996)
and Palatnik-de Sousa et al. (2004).
Figure 8: Model of VL progression in dogs used by Dye (1988) with SD, ED, ID being the
susceptible, latent and infectious dogs respectively and the ”never-infectious” population
is denoted here by RD.
SD ED ID
RD
λD σD
(1− q)
q
BD
Hasibeder et al. (1992) assume a very similar progress to that of Dye
(1988), however the model is subtly different by assuming that never-infectious
dogs can become seropositive, yet remain non-infective to sandflies. These
dogs may self-cure unlike their infective counterparts, returning to their orig-
inal status of uninfected and never-infectious. This underlying model struc-
ture makes no difference to the disease dynamics compared to Dye’s original
model, however including this extra infected dog class may help to link sero-
prevalence data better to the model. This model structure is also used later
by Courtenay et al. (2002b).
As with human infection, infected dogs can exhibit a range of clinical
signs from completely asymptomatic to severe, fatal infection. Current di-
agnostics through sera or blood eluates are able to detect latent and asymp-
tomatic infections (though with reduced sensitivity compared to infectious
dogs (Courtenay et al., 2002b)). Current tests cannot reliably identify infec-
tious dogs, though both the anti-parasite IgG antibody level and the parasite
load have been shown to be highly correlated with probability of infection in
sandflies during xenodiagnostic studies (Courtenay et al., 2002b, 2014).
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Figure 9: Model of VL progression in dogs used by Hasibeder et al. (1992) with “never-
infectious” population show as the bottom line. All dogs shown in the green circle are
infected and assumed seropositive, however only dogs in the red box, ID, are infective to
sandflies.
infected
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q
BD
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The most complex structure for ZVL is given by Costa et al. (2013a)
in their model which not only accounts for possible infective asymptomatic
dogs but also for imperfect screening due to diagnostic tools via the use
of extra compartments (see Figure 10). This modelling approach is more
sophisticated than its predecessors, with model equations corresponding to
this progression allow for delay between diagnosis and culling (discussed in
Section 4).
35
Figure 10: Model of VL progression in dogs used by Costa et al. (2013a). Here all dogs
are born susceptible but only some will develop symptoms after becoming infected and
passing through the incubation period. Dogs are screened at a rate r with sensitivity d, and
correctly categorised as diagnosed with symptomatic and asymptomatic infection, DS , DA,
respectively. Due to imperfect specificity dZ of diagnostic tools, some non-infected dogs
are incorrectly diagnosed DZ . All dogs within the green ellipse test seropositive. All red
boxes correspond to infective dogs, although asymptomatic dogs are around 3-fold less
infective to sandflies than those which are symptomatic.
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Table 2: Parameters associated with VL progression in dogs and their notation here and across modelling papers. All rates
are per capita unless stated otherwise.
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* = host-vector model. All others are based on vectorial capacity assumption for rate of infection (host-only model)
† = annual cull of seropositive: latent, infectious and non-infectious dogs respectively
‡ = transmission blocking vaccine
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2.3. The role of sandflies
Sandflies are key in the transmission cycle but little is known about some
important factors. In particular with models of vector-borne disease, it is
necessary to be able to estimate certain parameters in order to mechanisti-
cally model the role of the vector as part of the transmission cycle. These
factors include vector density, life expectancy and relative biting rates on
both humans and animals.
There are two different methods that are typically used to model host-
sandfly disease dynamics, both based on the Ross-Macdonald model (Ross,
1916; Macdonald, 1957), with the second method being a simplification of the
first. As is standard within vector-borne disease modelling for the first type of
Ross-Macdonald model, both host and vector equations are explicitly given.
Several VL models (see Table 3) use this explicit formulation with vector
equations described by the ODEs:
dSV
dt
= BV − λV SV − µV SV
dEV
dt
= λV SV − σVEV − µVEV
dIV
dt
= σVEV − µV IV
(2)
which use an exponentially distributed extrinsic incubation period (EIP) with
mean duration 1/σV . Alternatively the delay ODEs:
dSV
dt
= BV − λV SV − µV SV
dEV
dt
= λV SV − λˆV SˆV exp(−µV τ)− µVEV
dIV
dt
= λˆV SˆV exp(−µV τ)− µV IV
(3)
can be used where the caret denotes the variable evaluated τ days ago, i.e.
SˆV = SV (t − τ). This formulation has a fixed duration EIP of τ . In both
cases the rate of infection (ROI), often referred to as the force of infection,
towards vectors takes a similar form to:
λV = αpV
(IH + PH)
NH
(4)
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for L. donovani in human populations where α is the sandfly biting rate and
pV is the infectivity towards the sandfly. With this form of the ROI towards
vectors, both symptomatic cases of VL and PKDL are assumed to contribute
equally to infection in sandflies. Parameter notation associated with vectors
is found in Table 3.
In the case where PKDL does not occur (L. infantum) or for populations
of dogs (or other animals) the ROI is simply:
λV = αpV
IH
NH
(5)
Other additions used by Stauch et al. (2011, 2012, 2014), including infec-
tive asymptomatics and varying infectivity of HIV-positive individuals are
incorporated in a similar fashion but are not written here to retain a more
simple form. Amendments that can be made to consider the effect of addi-
tional animal populations are discussed later in Section 2.3.3.
The rates of infection for a “typical” vector-borne disease are usually
given in the form:
λH = αpH
IV
NH
λV = αpV
IH
NH
(6)
towards hosts and vectors respectively for a system with just one host in-
volved in the transmission cycle. This formulation for λH arises through an
infected vector, IV , picking a single host out of NH available hosts and bit-
ing at a rate α. The probability of the host being infected through a single
infectious bite is pH . The term λV is similar, with a single susceptible vec-
tor picking an infected host from the total host population with probability
IH/NH at a rate α and the probability of infection for the vector is pV per
bite on an infected host.
However sometimes the ROI towards hosts and vectors is given by:
λH = βH
IV
NV
λV = βV
IH
NH
(7)
with the denominator in the host equation being NV instead of NH . This
form is used by Mubayi et al. (2010) in their host-vector model of VL on the
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ISC and is one of the original variants of the Ross-Macdonald model (Smith
et al., 2012). Despite the apparent difference in formulation, this form is
used if host and vector populations are assumed to be constant, and so if
βH = αpHNV /NH and βV = αpV , the systems (6) and (7) are equivalent.
The second type of model, used particularly in those articles pertaining
to canine VL, uses an approximation method to implicitly include vectors
without the need for separate vector equations. Using the fact that sandfly
life expectancy is vastly smaller than that of humans or even dogs (µV >>
µH , µD) it is possible to separate the vector and host timescales with the
vectors equilibrating much faster than hosts (Williams and Dye, 1997). This
method takes one of the two forms above (either (2) or (3)) to find the
equilibrium number of infectious sandflies, and therefore a quasiequilibrium
(or pseudoequilibrium) approximation of the host infection dynamics.
The resulting approximation for the infectious vectors is:
I∗V ≈ NV
λV
(λV + µV )
× P(survive EIP) (8)
where the star denotes equilibrium, λV is as before (such as (4) or (5)) and
the probability of surviving the EIP is given by:
P(survive EIP) =

1 no incubation period
exp(−µV τ) fixed duration EIP
σV
σV + µV
exponentially distributed EIP(
nσV
nσV + µV
)n
gamma distributed EIP where shape parameter n
(9)
under various assumptions with the same mean duration used in the VL
modelling literature.
This may then be substituted into the ROI towards the host population(s)
by using:
λH = αpH
I∗V
NH
(10)
and so only host equations need to be explicitly written down.
In the case of VL, this approximation is almost always taken further by
considering the relative size of parameters in comparison to prevalence in
40
hosts, i.e. if µV >> λV . Under this new condition the equilibrium infection
in sandflies is given by:
I∗V ≈ NV
λV
µV
× P(survive EIP) (11)
In the case of endemic L. infantum infection in dogs in Brazil, dog infection
prevalence is around 19%, with a sandfly biting rate of approximately once
every 3 days (Reithinger et al., 2004), sandfly life expectancy of 14 days (this
is an upper estimate from the huge range of 2.4 (Dye, 1996) to 16.7 days
(Ribas et al., 2013)) and infectivity towards sandflies of 10.7% (Courtenay
et al., 2002b). Under this parameterisation µV ≈ 0.0714 and λV ≈ 0.0068
and so µV is an order of magnitude larger. Other less conservative estimates
for these parameters in this setting further increase the difference between
these two values, making the approximation quite reasonable, however in
some regions with higher host prevalence or alternate parameterisation this
assumption would not be appropriate. Care must also be taken to consider
the expected impact of control and seasonality on these approximations,
which might make them less appropriate.
This formulation is often favoured as it can be directly related to an
epidemiological measure, the vectorial capacity. The vectorial capacity is the
number of new cases occurring from all the bites taken on a single infected
person on one day in an otherwise na¨ıve population. It is usually denoted
by:
C :=
NV α
2pHpV
µVNH
× P(survive EIP) (12)
and so the ROI towards humans can be described in terms of the vectorial
capacity:
λH = αpH
IV ∗
NH
≈ α
2NV pHpV
µVNH
× P(survive EIP)× IH
NH
= C
IH
NH
(13)
which leads to a host-only model with the same type of frequency-dependent
contact rate used in contagious disease modelling (Anderson and May, 1992).
Several models of VL (Dye and Wolpert, 1988; Dye, 1988, 1996; Courtenay
et al., 2002b; Quinnell et al., 1997; Palatnik-de Sousa et al., 2004; Costa
et al., 2013a) utilise this vectorial capacity quasiequilibrium assumption.
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Finally, as is often the case with cost-benefit analyses, some models (Boe-
laert et al., 1999; Meheus et al., 2010; Lee et al., 2012) do not use a dynamic,
prevalence-dependent ROI and so the role of vectors is not considered at all.
2.3.1. The basic reproduction number
Alongside the vectorial capacity, another epidemiology measure known
as the basic reproduction number, or basic reproductive ratio, R0, is often
used when comparing disease in different regions or examining elimination.
Unlike the vectorial capacity which is primarily related to the vector’s capac-
ity to transmit disease and therefore is necessarily restricted to vector-borne
diseases, R0 depends on parameters associated with all parts of the infection
cycle and is widely regarded as the most useful measure across a range of
diseases (Keeling and Rohani, 2008).
For contagious disease in a homogeneously mixing population, R0 sum-
marises the number of new cases occurring directly from a single infected
individual in fully susceptible population without intervention. However for
heterogeneous populations with structured mixing or multiple species the
definition is slightly trickier (Rock et al., 2014). In its formal mathematical
derivation, R0 is defined using the next generation matrix approach (Diek-
mann et al., 1990); this computes the average number of secondary infections
from a “typical” infected individual. Here a “typical” individual may be a
host or a vector and the secondary infections, or the next generation, for VL
will always arise in the opposite population as hosts can only infect vectors
and vice versa. For basic VL models this method is not too complex.
In the case where vector EIP is assumed to be exponentially distributed
(2) and there is an SEIR host progression, the next generation matrix, K, is
calculated by writing down the matrices of transmissions, T , and transitions,
Σ, associated with the variables EH , IH , EV and IV of infected and infectious
hosts and vectors.
T =

0 0 0 αpH
NH
NH
0 0 0 0
0 αpV
NV
NH
0 0
0 0 0 0
 (14)
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Σ =

−(σH + µH) 0 0 0
σH −(γH + δH + µH) 0 0
0 0 −(σV + µV ) 0
0 0 σV −µV
 (15)
and the next generation matrix is given by:
K = −TΣ−1 (16)
Finally RNGM0 is the largest eigenvalue of the matrix, which is the spectral
radius of K:
RNGM0 = ρ(K) =
√
NV α
2pHpV
µVNH
σV
(σV + µV )
σH
(σH + µH)
1
(µH + γH + δH)
(17)
For VL that includes PKDL, alternate disease progressions or multiple hosts
this methodology can also be used. It can now be seen how R0 and the
vectorial capacity are linked:
(RNGM0 )
2 = C
σH
(σH + µH)
1
(µH + γH + δH)
(18)
Confusingly, for vector-borne disease, the basic reproductive ratio is often
considered to be the expected number of new cases in the host population
generated by a single infected host (Smith et al., 2007). As this is two in-
fectious generations, rather than one, this expected number of cases is the
square of RNGM0 given in (17). This version of the basic reproductive ratio,
called here Rfull0 , links to a full host-to-host cycle can also be derived using
the equations for the host-only model. Articles which use this version include
Dye (1996) and Quinnell et al. (1997) and arguably Rfull0 could be consid-
ered to be a more intuitive metric as it has a relatively simple biological
interpretation.
Conversion between the two versions of the basic reproductive ratio is
trivial and they agree on the same critical threshold value of R0 = 1, above
which a disease can invade a population and below which, it cannot. Caution
need only be taken when using the value of R0 as metric to compare either
disease in different settings or between different models; for example between
that of Dye and Wolpert (1988) (Rfull0 = 2.13) and Stauch et al. (2011)
(RNGM0 = 3.94, which gives R
full
0 = 15.5) who both model VL on the ISC.
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2.3.2. Sandfly host choice
Vector choice of host can be important to the spread of vector-borne
disease. The presence of secondary hosts plays a key role in reducing the
biting pressure upon the primary species, however if the secondary hosts are
also able to acquire and transmit the parasite they could become a reservoir
for infection. The concept of zooprophylaxis, where animals which are not
part of the transmission cycle are used to deflect biting away from humans,
has been suggested for other vector-borne diseases including malaria and
Chagas disease (WHO, 1982; Cruz-Pacheco et al., 2012).
On the ISC where the disease is thought to be anthroponotic, it is rea-
sonable to expect that additional animal populations have protective effects
for the human population by moving the biting pressure away from humans.
However the presence of animals close to the home may draw sandflies to the
area, resulting in higher vector densities and more risk. For the ISC studies
are conflicted about the protectiveness of cattle with some finding significant
protection and but others determining an increased risk (Bern et al., 2010).
For L. infantum, dogs are a known reservoir of infection and play a major
role in transmission whereas chickens could have a zooprophylactic role by
shifting biting pressure away from humans and effectively reducing the vector
to host density.
Biting behaviour of sandflies (P. argentipes on the ISC and Lu. longipalpis
in the New World) seems to be primarily opportunistic, however host biomass
is thought to play a role in host selection (Quinnell and Courtenay, 2009;
Bern et al., 2010). In addition to relative human-animal and human-vector
densities, this sandfly host preference will impact upon transmission unless
sandflies are motivated solely by convenience as has been described for other
vector-borne diseases (Rock et al., 2015b).
Despite this, not all modelling work integrates animal (or even multiple
animal) populations. Where animals are part of the transmission cycle, the
ROI towards the vector can be written:
λV = αpV
a(IH + PH) + (1− a)IA
aNH + (1− a)NA (19)
Where NA is the number of animals, IA is the number of infected ani-
mals, and a is the relative propensity to feed on humans rather than animals.
Stauch et al. (2011, 2012, 2014) later on discount animal reservoirs by set-
ting a = 1, but ELmojtaba et al. (2010a) use this type of ROI in their model
44
analysis to examine control via this reservoir (see Section 4.4). Even if ani-
mals play no role, the same formulation can be used with a < 1 but IA = 0
in order to model the reduction in biting due to presence of animals (i.e.
zooprophylatic effects).
2.3.3. Seasonality of sandflies
Seasonality of sandfly populations is considered to be substantial how-
ever it is not included in any models of VL on the ISC and only a handful
elsewhere (Salah et al., 1994; Mejhed et al., 2009; Williams and Dye, 1997;
Quinnell et al., 1997). Some non-modelling papers have sought to quan-
tify or qualitatively assess seasonal aspects of sandfly emergence or biting
(Singh et al., 2008; Rossi et al., 2008; Picado et al., 2010a) and a paper on
cutaneous leishmaniasis has incorporated detailed information about sandfly
dynamics into a transmission model (Bacae¨r and Guernaoui, 2006). Salah
et al. (1994) alter the host-vector transmission terms by means of a Boolean
function so that transmission only occurs during the warmer 5 months of
the year and Mejhed et al. (2009) use seasonal data of sandfly population
sizes from Morocco to parameterise the model over the course of a year. The
others, Quinnell et al. (1997) and Williams and Dye (1997), describe how
a host-only model of VL may be adapted to include seasonality by using
fluctuating vectorial capacity.
In reality there is a complex relationship between vector mortality/emergence,
EIP, human biting rate and temperature (as discussed by Hartemink et al.
(2011)), however to facilitate the modelling process, seasonality is usually as-
sociated with either change in vector emergence rate, or instead by varying
the transmission rate but keeping constant vector population size.
Figure 11 shows how using a sinusoidal forcing function of the form
(1+α1 cos(2pit)) on either the birth rate or the ROI affects the disease about
equilibrium for both host and vector populations. Although the two types
of forcing are fundamentally different the change in the resultant dynamics
and ROI between the two is slight (see Figure 12b); as would be expected,
forcing vector and host ROI shifts the peak of infection a little earlier than
forcing vector births as there is a lag between the influx of newly emerged
vectors and them biting and becoming infected. The most noticeable differ-
ence occurs within the vector dynamics; adjusting the ROI in this way has
no impact upon the vector population size, however changing the birth rate
does (see Figure 11c). Consequently, whilst very similar dynamics in the
host population are seen in these two cases, the prevalence measured in the
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vector population across the year shows a marked difference, reaching very
high prevalence just before the coldest part of the year using forced births.
Under a forced birth rate RNGM0 will be slightly underestimated (by
α1/8% where α1 is the amplitude of forcing in the function given above)
(c.f. Bacae¨r, 2007). Williams and Dye (1997) describe how this is related to
changes in incidence and how it will affect the net reproductive ratio and its
thresholds. In the typical case where per capita host death and recovery rates
are taken to be constant and forcing is on the vectorial capacity, then the
arithmetic mean dictates the overall dynamics and so the critical threshold
of R0 = 1 still holds. Additionally, in the case of vector-borne disease in-
cluding ZVL, knowledge of varying incidence (which can be measured in the
field) in the host population can be used to calculate R0 as average incidence
corresponds to average vectorial capacity.
Seasonality in ROI can be critical in interpretation of surveillance data
and in model predictions of intervention outcomes. Repeated data on sandfly
population size and infection prevalence is required to fit models that include
seasonality. The mechanistic functions suggested above could be combined,
and other mechanisms included. If seasonality is due to environmental vari-
ables, such as rainfall and temperature, then there is no reason for them to
follow particular patterns, which further complicates data requirements and
ability to forecast accurately.
Other options for season forcing include Boolean transmission where trans-
mission occurs only at certain times of the year and not in others, for example
the 5 warmest months out of the year (after Salah et al., 1994). Figure 12
demonstrates how altering the biting function in this way compares to the
previous sinusoidal biting function.
There is clearly a need for regular sampling to estimate vector parameters
across the seasons to better inform fluctuating transmission from sandflies.
Sampling frequency needs to be of the same order of magnitude as the gen-
eration time. Inadequate sampling frequency, e.g. annual, cannot discern
sandfly dynamics and could even give a distorted picture of average sandfly
prevalence or rate of infection towards host populations. Mejhed et al. (2009)
indicate that May/June and October are the two times of the year when there
is the highest values for R0 and so highest levels of transmission in Marrakech,
Morocco. Similarly, on the ISC, Picado et al. (2010a) argue that IRS should
be carried out in Feb/March and August/September based on seasonal pat-
terns observed in their sandfly density studies in India and Nepal. However
a study in Bihar, India which examined sandfly infection as well as density
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Figure 11: Simulations using no forcing and sinusoidal forcing on the birth rate and ROI
respectively. (a) shows the expected change in level for susceptible (green) and infected
(red) host and vectors for a SEIR host/SEI vector model. (b) shows how the ROI will
change under the three assumptions and (c) compares the population size and percent
prevalence of infection in the vector population under forced births and forced ROI.
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Figure 12: Simulations using no forcing and sinusoidal/boolean forcing on the ROI respec-
tively. (a) shows the expected change in level for susceptible (green) and infected (red)
host and vectors for a SEIR host/SEI vector model. (b) shows how the ROI will change
under the three assumptions.
found that whilst abundance was highest during August/September, preva-
lence in sandflies was greatest in November/December (Tiwary et al., 2013).
Such results warrant further investigation into the seasonality in all endemic
regions, especially when planning the timing of vector interventions such as
IRS.
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Table 3: Parameters associated with VL in vectors and their notation here and across modelling papers where they are
explicitly included. All rates are per capita unless stated otherwise.
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(
2
0
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3
)
total birth rate µVNV δFNF A2(t) µFN varies ΛV - αFNF - µs(s2 + s3)
death rate µV δF µ2 µF µ2 µv µv µF µsf µs
total biting rate α - - a 2a 2a C β a ah + ad
human biting rate αa - - a(1− p) a a - βa - ah
dog/animal biting rate α(1− a) - - ap a a - β(1− a) a hh+x ad
susceptibility to infection pV βAF
 β2  c b1 c βvh pF1, . . . , pF4† c c
mean EIP σ−1V LF * τ* τ* - - γ
−1
v *** σ
−1
F ** EIP* τ*
ratio of vectors to hosts m = NVNH NF /ND N2/N1 m
V
H ,
V
R ‡ n m NF /NH v/h mh,md‡
=includes biting rate
*=fixed duration EIP
**=exponentially distributed EIP
***=gamma distributed (n = 25) EIP
†=dependent on status of infective human (i.e. symptomatic/asymptomatic etc.)
‡=on humans and dogs respectively
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3. Data-Model Interactions
3.1. Current data and initial models
In any model, individuals have to have a defined infection state. For
compartmental models, these states are mutually exclusive, for example,
susceptible (uninfected) and infected. There are two general approaches to
fitting models to data. First, individuals are unambiguously assigned to one
compartment/state on the basis of diagnostic tests, and the numbers of in-
dividuals in each diagnostic category is compared to model prediction (e.g.
Stauch et al., 2011, 2012, 2014; Chapman et al., 2015). Alternatively, the
model states can be related to population data through diagnostic character-
istics, i.e. the model can predict the prevalence of positives (true and false)
for a given infection prevalence. The latter approach is most often related
to age groups (e.g. Rodriguez-Barraquer et al., 2014). In either case, but
especially the former, the information in the data, and therefore the accuracy
of parameter estimates, is greatly enhanced if the data are longitudinal, i.e.
multiple measurements from the same individuals through time (e.g. Chap-
man et al., 2015). Time series data arise from repeated measurements in
the same population, but not necessarily the same individuals; an example
is data relating to cases in a defined population over time. Age-related data
are more informative than simple prevalence data, as age measures duration
of exposure, and can serve as a proxy for time. Having defined the states
in the model that can be related to data, the states have to be defined in
terms of their duration and their infectiousness. These data can be inferred
during a fitting process, or, better, estimated independently from research
data. As has already been discussed, a major complication with Leishmania
infection is that precise, gold standard diagnostic does not exist. In a mod-
elling context, a diagnostic is good if it is accurate and matches well with
compartments required in the model. Of course, modellers will frequently
choose compartments that match with diagnostics, and Stauch et al. (2011,
2012, 2014) is an one such example. In contrast, diagnostics and vector mea-
surement are more advanced in malaria, which has inspired a plethora of
modelling approaches (Smith et al., 2014).
The dynamics of the vector population directly impact the observed VL
transmission dynamics. However, several of the parameters associated with
the vector are hard to ascertain and consequently there are great uncer-
tainties in the parameterisation of models, in particular with those which
explicitly model vector populations. The density of sandflies and their abun-
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dance relative to both human and animal hosts are not only difficult to
determine but are known to vary greatly between different regions, for ex-
ample, see Hartemink et al. (2011) who used geographic sticky trap data to
estimate densities and map R0 in France. Likewise the seasonal fluctuations
of sandfly populations are hard to pin down and so are not featured in many
transmission models of VL at present. Even something as fundamental as
sandfly life expectancy has large confidence intervals and whilst models typ-
ically use an estimate of 2 weeks, they range from 2 days to an unlikely 2
months.
One way to make progress without this information is to create host-only
models which use the vectorial capacity, C, to infer the host-vector com-
ponent of transmission. Although this is useful for initial models, and is
consistent and efficient from a modelling view point, the value of C is still
reliant on estimating several vector parameters, and the usual assumption
that the quasiequilibrium assumption is valid. We are also missing accurate
assessment of the infectiousness of different host classes to sandflies, and
again, in order to make progress, simplifying assumptions have to be made,
for example, Stauch et al. (2011, 2012, 2014) use pV = 1 for the probability
of a sandfly acquiring infection from an infected human. Of course, with-
out information on sandfly biting rates, this assumption doesn’t matter, as
doubling the sandfly population and halving pV will give the same results.
Parameter combinations such as R0 and C summarise both the model and
unknown data into a single number.
A feature of simple models of infectious disease is that apart from the
infection state, and perhaps age, all individuals are considered as equal rep-
resentatives of the average individual, and all are equally likely to transmit
to each other. However, there will be considerable heterogeneities in terms
of, for example, response to infection, and exposure to vectors. If this het-
erogeneity is great, then the concept of an average might be wrong (e.g. Dye
(1986); Smith et al. (2014)). The consequence of mistakenly believing indi-
viduals are all essentially equal is usually to under-estimate the control effort
required (i.e. to underestimate R0), as there are sections of the host-vector-
parasite population combinations that are transmitting at a much higher
rate than the rest. For Leishmania in particular, there is sufficient field ev-
idence to suggest that rates of transmission and disease vary significantly
through both time (Dye and Wolpert, 1988) and space (Bern et al., 2007;
Woolhouse et al., 1997), and between individuals (Courtenay et al., 2014) so
that there is unlikely to be a good “average” situation. But without sufficient
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data to understand the important spatio-temporal scales, the correct scale
of appropriate spatio-temporal studies is unknown; for example, is annual
assessment of a village sufficient, or should studies be based on monthly as-
sessment of households in at least five villages? For malaria, spatio-temporal
hotspots have been identified at the household-month level (Bejon et al.,
2014). Broad estimates may still help in planning widespread interventions,
but more detailed information could help target interventions in key foci at
optimal times.
As well as space and time, host-parasite-vector populations can differ
by genetic, socio-economic and environmental variables. The importance of
dimensions is likely to be different at different times and places – for example
during an epidemic, the socio-economic factors might change. Unless the
correct scales are known, the danger is that any one study gives only a partial
picture, and piecing the studies together is fraught with difficulty due to, for
example, difference between epidemiology stages and variation in diagnostics.
Additionally, highly variable diagnostics are also going to potentially mask
important heterogeneities, i.e. the noise will swamp the signal.
3.2. Future data and alternative sources
Given the relative paucity of data that can be used to develop accurate
models, can we identify alternative sources of data, and define from current
models and understanding, what data ought to be collected?
Working with animal models of infection and disease has the considerable
benefit that it is possible to conduct experiments (e.g. deliberate infection),
but the disadvantage that the results might not transfer directly to humans.
Studying canine, zoonotic VL has the advantage that parameter estimates
can directly inform models relevant to zoonotic human disease, as well as,
in the absence of direct data, informing anthroponotic transmission mod-
els. Whilst the quantitative parameter estimates are unlikely to be directly
transferable, the processes might be directly parallel to humans. For exam-
ple, infection rates of sandflies from xenodiagnosis experiments in dogs have
been shown to correspond to a threshold density of Leishmania parasites in
skin snips taken from ears (Courtenay et al., 2014); so whilst the numeri-
cal values of transmission probabilities are for dog-sandfly interactions, it is
likely that same biological process occurs in human-sandfly interactions. It
is possible to perform xenodiagnosis directly in people, and there are cur-
rently attempts to conduct such experiments (Miller et al., 2014). Similarly,
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it is possible that the natural history of disease is related to the size of the
inoculating dose of infection (Bern et al., 2010).
Longitudinal and time series data will be critical to future model de-
velopment. The transmission dynamics at the population level (i.e. the
processes that determine the public health impact of VL), are derived from
the processes within individuals: infection, immunity, pathogenesis and in-
fectiousness. We need to know the natural history of infection, and particu-
larly the performance of current and future diagnostics, over long periods of
time. This can come from cohort studies, but also from accurate case series
in defined locations, perhaps supplemented with cross-sectional data from
the same populations. To our knowledge, there is no dataset available from
the ISC or elsewhere which has longitudinal measurements on humans, and
repeated measurements on vectors.
4. Modelling Interventions
4.1. Humans
4.1.1. Diagnostics
Diagnostic tools are a key part of the targeted control strategy for VL in
order to accurately diagnose and treat individuals, and to monitor incidence
and prevalence in the population. In addition to these primary uses, diagnos-
tic tests for VL can also aid in developing and parameterising mathematical
models of disease; enabling individuals to be placed into one of the mutually
exclusive compartments.
For VL in humans some of the main diagnostic tools which can be used to
screen people are PCR, ELISA, DAT, LST and rK39 (a rapid diagnostic test)
as described in Section 1.1.2. Whilst some study sites may use a combination
of tools to determine presence of the parasite, antigens or antibodies, often
just a single test will be used to make a diagnosis. Given that mortality of the
disease is associated with clinical symptoms, only those displaying outwards
signs of infection are usually tested and subsequently treated.
Stauch et al. (2011, 2012, 2014) use three different diagnostics (PCR/LST/DAT)
to partition the human population under their model, however the model does
not account for imperfect tests. Furthermore, whilst the accuracy of tests
such as PCR and DAT has been well analysed for detecting KA, they have
unknown sensitivity and specificity for asymptomatic infection.
Using a cost-effectiveness analysis Boelaert et al. (1999) compared four
alternate diagnostic strategies to find the most effective (most deaths averted
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compared to no intervention) and the most cost-effective (the lowest cost per
death averted). The strategies are outlined in Table 4 and were based on
treatment using antimonials. The authors found that for expected baseline
estimates for prior probability in suspected clinical cases (40%), that strategy
A was most effective and B was worst. For lower probabilities of infection
the most effective strategy changed with A causing more deaths (through
possible treatment toxicity) than it averted. This result has important im-
plications: as prevalence reduces, moving forward to elimination, it suggests
that strategies may have to change as the prevalence of disease in the popula-
tion decreases. The most cost-effective strategy was B at a cost of US$448 per
death averted. This analysis was published in 1999 and was based on the cost
and accuracy and of drugs and diagnostics at the time. With new diagnostic
developments, lower incidences and newer drugs, the available strategies and
their (cost-)effectiveness need to be continually reevaluated.
Table 4: Competing diagnostic and treatment strategies analysed by Boelaert et al. (1999)
in the Sudan.
Strategy Description
A Treat all clinical suspects
B Perform parasitological diagnosis
on clinical suspects and treat if
positive
C Perform DAT test on clinical sus-
pects and treat if high titre. If
borderline DAT results then par-
asitological diagnosis and treat-
ment if positive.
D Perform DAT test on clinical sus-
pects and treat if high titre
Recent work (Medley et al., In Press) highlights the importance of early
diagnosis and treatment of KA patients, if they are responsible for the major-
ity of transmission (i.e. if asymptomatics are not responsible for maintaining
transmission). It also potentially explains why current control programmes
in the ISC have been successful despite the apparent ineffectiveness of vector
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control (Coleman et al., 2015). Results from this model suggest that a diag-
nostic test with only 50% sensitivity might result in a considerable reduction
(halving) of R0 and offer the potential for elimination. However, low speci-
ficity of a diagnostic test (i.e. the false positive rate) would prevent it being
applied to individuals with non-specific clinical symptoms. These results
suggest that a diagnostic test with high specificity, even at the expense of
relatively low sensitivity, is required for wide spread intervention. As elimi-
nation is approached, false positives will always become more significant, and
the specificity of tests more important. However, most consideration of test
characteristics during development concentrates on sensitivity.
4.1.2. Treatment
Treatment of KA plays an important part in control programmes, primar-
ily as the disease is usually fatal without it. However, as treatment reduces
the number of KA patients, it will also reduce the ROI towards the sandfly.
The shorter the timescale between onset of KA and successful treatment, the
smaller the infectious pool of people will be. However, this effect may be
small if asymptomatics are important in transmission (Stauch et al., 2011).
For the Sudan, ELmojtaba et al. (2010a) examined the impact of first-line
treatment for KA; analysis varied both treatment rate and effectiveness of
preventing PKDL (i.e. f). With high treatment alone there is a reduction
in symptomatic VL cases but since (1 − f) of these treatments produce a
PKDL case, infection rates were still high. Increasing both treatment and f
was unsurprisingly more effective. Unfortunately the PKDL treatment rate
was not varied to simulate extra treatment efforts with this class of patients.
The model of Stauch et al. (2011, 2012, 2014) includes three treatment
types: first line treatment of VL (at a rate τ1), second line treatment of VL
following first line treatment failure (at a rate τ2) and finally PKDL treatment
(at a rate τ3). First line treatment failure occurs with probability p1 = 5%
and PKDL follows after treatment and remission with probability p2 = 3%
from successful first line treatments and p4 = 3% from second line treatments
(all conditional on surviving treatment with probability (1 − fT ) ≈ 0.95).
Second line treatment is always assumed successful upon survival, in that
individuals appear recovered at least for a time before PKDL. The authors
found that whilst treatment was clearly necessary from an individual KA
patient’s perspective and did decrease the prevalence of KA, increasing effec-
tiveness or time to treatment made a negligible different to the underlying
disease dynamics. If this is the case and the objective is to minimise occur-
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rence of KA, then the benefit will only be gained whilst treatment continues
at a high level; once the treatment returns to the original level, the preva-
lence will also bounce back. Stauch et al concluded that the limited effect
of treatment alone on the incidence of KA was primarily due to infective
asymptomatics. In fact, under their parameterisation, there would still be
over 15 KA cases per 10 000 in this endemic setting. The difference between
the conclusion of Stauch et al and that of Medley et al is entirely due to
assumptions about the relative infectiousness of symptomatic and asymp-
tomatic cases. The apparent clustering of KA cases and recent success of
KA treatment in reducing VL in ISC are both evidence for KA cases being
the predominant source of infection to sandflies. On the other hand, asymp-
tomatic cases are numerous and may be significantly infectious. Only field
data can resolve this difference.
A cost-effectiveness analysis by Meheus et al. (2010) compared the use of
different treatment options (either currently available or in Stage III trials)
on the ISC. This study differed from Boelaert et al. (1999) in geographic
location, but also Meheus et al assumed patients were correctly identified
prior to treatment, whereas Boelaert et al assumed all patients received the
same treatment. The 10 alternate treatment strategies included a range of
mono- and combination-therapies with each having associated pros and cons
such as the requirement for cold-chain storage, cost, length of treatment and
toxicity. The most cost-effective strategy was combination Miltefosine (MIL)
and paromomycin (PM) treatment at a cost of US$92 per death averted.
The authors found that a possible future decrease in the cost of liposomal
amphotericin B (L-Amb) compared to MIL might change the most cost-
effective strategy to combination L-Amb and PM.
4.1.3. Human vaccine (theoretical)
A prophylactic vaccine would reduce the human incidence by reducing
the numbers of susceptibles who are able to acquire Leishmania infection,
or reduce the proportion of those infected who develop disease. The former
vaccine provides protection to those who have been vaccinated, but also
indirect protection to the non-vaccinated as there are fewer people infected.
The latter, disease preventing vaccine does not prevent the acquisition of
parasites, but alters the progression so that people do not develop KA. This
latter vaccine type is currently the a promising candidate for use in the near
future; however asymptomatic individuals who do not develop KA may still
remain infectious, so there may possibly be less indirect protection to the
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Figure 13: This diagram shows the incremental cost-effectiveness ratio (ICER) compared
to the per capita GDP in Bihar . It also shows the ranges given by Lee et al. (2012) for
“highly cost-effective”, “cost-effective” and “not cost-effective”.
non-vaccinated.
Lee et al. (2012) use a cost-effectiveness analysis to address the potential
impact of a human vaccine for VL. Unlike the other cost-effectiveness pa-
pers which examine the cost-effectiveness per death averted (Boelaert et al.,
1999; Meheus et al., 2010), Lee et al use disability adjusted life years (DALYs)
avoided as their measure. The incremental cost-effectiveness ratio (ICER)
per DALY averted is compared to the per capita gross domestic product
(GDP) in Bihar of US$288 and is designated “highly cost-effective”, “cost-
effective” or “not cost-effective” (see Figure 13). In this analysis, the vac-
cine is assigned an efficacy, with 50% efficacy meaning an individual has a
probability of 0.5 of becoming immune to infection following vaccination. A
successfully vaccinated individual therefore will not only avoid KA but also
possible PKDL.
Based on treatment with amphotericin B and an imperfect diagnostic
test (rK39), Lee et al found that the vaccine was cost-effective when it cost
US$100 or less per person and had at least 25% efficacy. If the efficacy was
increased to 50%, and the price was less than US$30 then vaccination could
even be cost-saving compared to treatment alone. The analysis made use of a
fixed ROI in simulations, as did Boelaert et al and Meheus et al. Such analy-
ses will always underestimate the effectiveness of a vaccine, as the model does
not predict any indirect protection, i.e. they assume that successfully vacci-
nating 50% of the population does not change the risk in the non-vaccinated
(Edmunds et al., 1999). This approach also ignores the longer-term dynamic
impacts of vaccination and the possibility of elimination. However, given the
paucity of well validated dynamic models of VL, assuming a constant ROI is
reasonable.
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4.2. Vector
Interventions that target vectors generally change a combination of three
parameters: the biting rate on the host population, α, vector mortality, µV ,
and the number of vectors, NV . Indoor residual spraying (IRS) is likely to
increase mortality and hence reduce the number of vectors but might not al-
ter the human biting rate of the remaining sandflies. The biting rate can be
directly reduced by use of effective bed nets, which may be impregnated with
long-lasting insecticides (LLINs). Deltamethrin-impregnated collars (DMC)
on dogs provide the dogs with protection from sandfly bites via an excito-
repellency effect whilst the insecticidal effect kills sandflies. At present there
are no proven effective methods for reduction of sandfly populations by tar-
geting non-adult stages. IRS, LLINs and collars only likely impact on indoor
populations but not on the (outdoor) sandfly population as a whole; although
this may be sufficient to reduce biting pressure to humans.
4.2.1. On the ISC
Whilst examining vector control was not the main goal of Stauch et al.
(2011), it was found that a reduction of 80% of vector density would be
needed in order to push R0 below one and achieve elimination. A second,
more detailed, study of vector interventions using the same model (Stauch
et al., 2014) considered the impact of different types of vector control on sand-
fly dynamics. IRS and LLINs were both considered to kill vectors directly,
increasing their mortality rate, µV , which had a knock-on effect by reducing
vector density (NV /NH). Environmental vector management (EVM), linked
here to plastering of houses, was assumed to destroy available breeding sites
and therefore reduce the number, NV , of vectors.
Stauch et al. (2014) found that under the first strategy (increasing mortal-
ity), elimination could be achieved if there was a reduction of 67% in sandfly
density, whereas if the direct approach (through EVM) was taken, a higher
reduction of 79% was needed. For the ISC in general, neither LLIN nor
EVM were found to be suitable interventions on their own, as field estimates
of expected density reduction were not high enough. LLIN in Bangladesh
could be viable with reductions in intra-domestic sandfly density reaching
70-80% (as measured by CDC light traps) (Joshi et al., 2009), but in India
and Nepal bed nets have not had such success. IRS was found to be a feasible
intervention strategy because it has been shown to reduce densities by 72%
(higher than the required 67%). The model also compared sole interventions
to a combined approach and found that, for example, a 42% reduction via
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EVM (as seen in the field) would require a further 50% reduction via IRS in
order to reach the critical threshold.
4.2.2. In Africa
ELmojtaba et al. (2010a) examine control of the vector population in
their model through reducing the biting rate corresponding to interventions
including bed nets or ensuring clothes cover the body. ELmojtaba et al found
that vector control was by far the most effective intervention compared to
various human treatment strategies (although the biting rate was reduced for
both humans and reservoirs) as this control reduces not only the infectious
pressure on susceptible humans but also the ROI on the sandflies from all
infective individuals (including PKDL). Whilst this model does not include
asymptomatics, it is interesting to note that this logic extends to them as
well and it should be expected that bed nets work well at reducing the con-
tribution of infection from all humans, regardless of whether their disease
status is known/treated.
4.2.3. In Brazil
Dye (1996) and Ribas et al. (2013) used another similar approach to
model control for humans. Both incorporated (direct) insecticidal vector
control such as IRS by increasing vector mortality in their models. The
results are congruent; it was found that vector control has a large impact
upon prevalence in humans and was by far the best control method out of
the several suggested. Even though Dye found that prevalence in the dog
population was lower under treatment than under quite modest insecticide
interventions, the reduction in the total bites taken caused by increasing
vector mortality was sufficient that insecticide was still the best option for
reducing transmission to humans where they are a spill-over host.
Ribas et al. (2013) examine the use of DMC in their model by altering
the ROIs to and from dogs:
λD =
αD
θ
pD
IV
ND
and λV =
αD
θ
pV
ID
ND
(20)
or under re-parameterisation
λD = αD(1−B)pD IV
ND
and λV = αD(1−B)pV ID
ND
(21)
where
1
θ
= (1−B) and 0 ≤ B ≤ 1.
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Here B can be though of as the proportion reduction in biting. Using this
model structure, Ribas et al found that collaring was reasonably effective at
prevention infection and could dramatically reduce prevalence in humans if
the protection offered by the collars was high.
Figure 14: Model of collaring by Reithinger et al. (2004). The subscript CD represents
those dogs which have been collared, which occurs at ρC = 80% of the dog population per
year (in a single pulse). Collars loose effectiveness or are removed/lost at a continuous
rate of ξC = 0.001 per day. Collared dogs have 90% protection from sandfly bites.
uncollared
collared
90% reduction in bites
SD ED ID RD
SCD ECD ICD RCD
λD σD γD
ρCξC
0.1λD σD γD
ρC ρC ρCξC ξC ξC
Reithinger et al. (2004) took an alternative approach by adding an addi-
tion compartment to their model. Here pulse collaring of 80% of dogs was
simulated either 1 or 2 times per year with DMC losing effectiveness con-
tinuously over 8 months. The results were found to be dependent upon the
demography of the dog population with a lower average life expectancy mak-
ing collars a more effective strategy. Simulated DMC effects did not vary
greatly with change in endemicity. In contrast, baseline prevalence levels
impacted quite substantially upon culling success.
These DMC models examined a reduction in biting for dogs with collars
but did not consider the possible effects of either an associated increase in
mortality of sandflies from feeding attempts on collared dogs, or displaced
bites (and subsequently higher biting) on uncollared dogs. These two addi-
tional effects might be expected to decrease or increase the total prevalence
respectively. Insecticidal effects of collars would not stop transmission from
infected flies to susceptible dogs but would prevent dog to fly transmission
as sandflies would either not feed or die before passing through their EIP.
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4.3. Dogs
4.3.1. Diagnostics
Courtenay et al. (2002b) examined the infectious states of a naturally
exposed cohort of dogs by xenodiagnoses in order to appropriately model the
dog population by partitioning into never/ever-infectious categories (used by
Hasibeder et al., 1992). They used the sensitivity/specificity of the different
diagnostic tools to simulate which dogs would be identified as seropositive
during screening. The authors found that insensitivity of the diagnostic test,
as well as delays between diagnosis and culling, could explain why a culling
intervention might fail. In a follow-on study, Courtenay et al. (2014) used
qPCR to quantify heterogeneities in L. infantum burdens in canine tissues to
relate to their infectiousness to sandflies, and demonstrated that qPCR could
identify the majority of infectious dogs and potentially distinguish highly in-
fectious from non-infectious animals. In their model they demonstrated that
a small proportion of dogs were responsible for the majority of transmission
events.
Costa et al. (2013a) use the sensitivity and specificity of diagnostics in
their model which includes infectious symptomatic and asymptomatic dogs
(with asymptomatic dogs assumed to be 3 fold less infective to sandflies than
those with symptoms), as described previously and visualised in Figure 10.
Under the model the sensitivity and specificity of the diagnostic were both
assumed to be within a range of 80–100% and were assumed to be the same
for symptomatic and asymptomatic dogs (which is unlikely to be true). The
model results indicate that the presence of asymptomatic dogs impacted the
control strategies and time scales negatively; the authors concluded that
models without asymptomatics might over-estimate the effectiveness of in-
terventions reliant on diagnostic tools such as culling. In higher prevalence
areas the control of the asymptomatic dog population was necessary to re-
duce transmission below the threshold level. In this case high sensitivity tests
would be needed to find the asymptomatic reservoir, whilst high specificity
tests reduce the numbers of dogs needed to be culled and critically, reduce
the unnecessary culling of false positives. This indicates that optimal strat-
egy is likely to depend upon regional prevalence. As screening is costly it is
likely that this would only be cost-effective in higher prevalence areas.
4.3.2. Treatment
Unlike VL in humans, treatment of disease in dogs is not part of national
control programmes: nevertheless it is possible to treat dogs for infection
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with drugs. Only two articles pertaining to dogs included the effect of treat-
ment of infected dogs in their models (Dye, 1996; Ribas et al., 2013). In both
articles, the same approach was taken, whereby a constant treatment rate
was assumed, presumably corresponding to ad hoc detection of infected dogs
via their symptoms. However Ribas et al assume that dogs will become sus-
ceptible to disease once more post-treatment rather than retaining immunity
from re-infection as assumed by Dye. This difference has huge implications
for modelling results and explains the stark discrepancy in conclusions drawn
by these authors; Ribas et al found that treatment of infected dogs had vir-
tually no impact on overall prevalence of infection (in humans) whereas Dye
found it to be moderately beneficial at reducing prevalence. In reality, dogs
may relapse to a diseased state, not through re-infection, but rather through
recrudescence of parasites post-treatment as treatment is rarely curative.
4.3.3. Dog culling
Unlike the strategies to control VL in humans, there are alternative op-
tions for intervention in animal populations. The first of these interventions
is to cull infected dogs in order to reduce the ROI towards the sandfly; this
intervention has been posed as a viable strategy in Brazil and has had seem-
ingly beneficial effects in China (when employed concurrently with insecti-
cide) (Zhi-Biao, 1989). Some authors (Dye, 1996; Palatnik-de Sousa et al.,
2004; Costa et al., 2013a) implement culling in models in a similar way to
which treatment is modelled by Ribas et al. (2013), that is, a diagnosis of
infection is made either via symptoms or ongoing screening and culling will
subsequently occur at some constant rate throughout the year with the re-
moved dogs being replaced with an influx of susceptible dogs (or puppies).
In contrast, other authors (Courtenay et al., 2002b; Reithinger et al., 2004)
opt to model a pulse culling campaign where dogs are annually removed af-
ter mass screening (50% screening in Reithinger and 100% in Courtenay).
Courtenay et al assume that removed dogs are “rapidly” replaced by suscep-
tible ones, while Reithinger et al use a dog recruitment method where the
population returns to equilibrium over time at a rate described by:
µ¯VNV + β
(
1− NV
K
)
NV (22)
where µ¯V is the weighted average mortality rate from both natural death and
infection, β is the density dependent growth rate of the population and K is
the carrying capacity of the population at equilibrium.
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The second form of replacement is more realistic as an area could not re-
place all their dogs instantly. As culled dogs will be replaced with susceptible
ones, unsurprisingly most authors conclude that culling is not likely to be the
best option available. Dye (1996) found it to be the worse option amongst all
posed strategies by using a maximum cull rate of infectious dogs of around
4% per month in his analysis. Costa et al, used a 4% screening of symp-
tomatic dogs per month (which would result in an even smaller proportion
being culled) with a 4-month delay before culling. They found that whilst
this was sufficient to reduce transmission to less than 1% in low transmission
settings, that high-endemicity regions would need to cull a minimum of 30%
of asymptomatically (but infectious) dogs to achieve the same results. Costa
et al also emphasised how, if screening the whole dog population, 79% of
those culled would have been removed unnecessarily using a diagnostic test
with 80% specificity.
Palatnik-de-Souza et al and Ribas et al examine much higher rates of
culling assuming homogeneity in infectiousness with the former determining
that 7% of infectious dogs must be removed per day to reduce R0 below the
critical threshold of one, and the latter concluding that below 18% culling per
day there would be virtually no impact on disease transmission to humans.
One group, Reithinger et al. (2004), found culling to be moderately effec-
tive at reducing prevalence of infection in dogs. In particular, increasing the
percentage of infected dogs culled and/or the frequency of screening cam-
paigns (from one to two pulses per year), made a significant reduction to
the prevalence. Culling had higher relative effectiveness in low transmission
settings compared to high transmission areas.
In summary of existing culling models, culling can be made more effective
by reducing time between diagnosis and culling, and by improving the sen-
sitivity so that a higher percentage of infectious dogs are identified. There
needs to be a (perhaps unrealistically) high screening coverage and rate to
achieve substantial reduction in disease burden. Specificity of diagnostics
must be increased if all dogs are to be screened in order to reduce incorrect
diagnosis and culling of non-infectious dogs which in turn should increase
dog owner compliance (Costa et al., 2013a; Courtenay et al., 2014). In par-
ticular it would useful to have a tool to differentiate between infected and
infectious dogs to minimise the level of culling needed and target this control
effectively (Courtenay et al., 2002b). Culling of healthy uninfectious dogs
should be avoided from an ethical perspective.
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4.3.4. Dog vaccination
Often when vaccination is considered in models it is assumed to be pro-
phylactic with individuals gaining immunity (or partial immunity) with suc-
cessful inoculation. Such a (fully) prophylactic vaccine model is used by Dye
(1996) to examine the potential effect of immunisation of a dog population;
he found that at low levels of intervention, vaccination would be one of the
best strategies, although insecticides may more easily eliminate disease at
higher levels of intervention. Under Dye’s parameterisation, around 90% of
the susceptible dog population would have to be successfully vaccinated in
order to achieve elimination.
Aside from prophylactic vaccine, other types of vaccine which have been
developed for other diseases could potentially provide an alternative inter-
vention for VL. One which has been modelled in a dog population is a
transmission-blocking vaccine, in which a vaccinated dog may still acquire
infection, but upon becoming infected they will have a reduced infectivity
towards sandflies through reduced development of the parasite within the
vector (Ribas et al., 2013).
In the model by Ribas et al Ribas et al. (2013), the ROI towards the
vector is amended from:
λV = αDpV
ID
ND
(23)
to includ this reduced infectivity:
λV = αD
pV
ν
ID
ND
(24)
or under re-parameterisation:
λV = αD(1− T )pV ID
ND
(25)
where
1
ν
= (1− T ) and 0 ≤ T ≤ 1.
Here, T might represent the vaccine efficacy, i.e. T = 1 is 100% effective
at blocking transmission and T = 0 is 0% effective given all the dog popu-
lation is vaccinated. Alternatively T could be the proportion of successfully
vaccinated dogs in the population. In the first case the infectivity parameter,
pV is essentially reduced by a factor of (1− T ), whereas in the latter, just a
proportion (1 − T ) of dogs remain unvaccinated and since vaccination does
not prevent dogs becoming infected, the same proportion, (1 − T ) are fully
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infective to dogs whilst the rest are non-infective. Either of these results in
the same mathematical formulation of the ROI.
Under this formulation, the transmission-blocking vaccine was simulated
and found to be marginally better at reducing prevalence in humans (consid-
ered to be a spill-over host) than treatment of dogs, however as the interven-
tion impacts only on infectivity of some blood-meals and does not directly
affect sandfly feeding rates or mortality, the intervention did not have a pro-
nounced effect upon human prevalence.
In the case of VL, transmission-blocking vaccines may also prevent dis-
ease in dogs (but not infection) as both symptoms and infectiousness are
correlated with parasite burden. Consequently there may be less of a dis-
tinction between prophylactic and transmission-blocking vaccines for ZVL.
Future canine vaccines may also have a curative effect if given to a diseased
dog; this effect has not been explicitly modelled.
4.4. Other animal hosts
ELmojtaba et al. (2010a) found that the presence of other animal popu-
lations which are able to acquire and transmit VL would increase the preva-
lence in humans, however at present no other animals have been shown to
be reservoirs (Quinnell and Courtenay, 2009). The presence of additional
host populations and their impact on the primary population is non-trivial;
in large enough numbers the secondary host population removes biting pres-
sure away from the primary hosts (humans) and consequently this may in
fact reduce the ROI upon primary hosts. Conversely the additional popula-
tion(s) may drive infection in the primary hosts, or, in this case, stifle the
effects of control upon just the primary population through treatment of in-
fective VL humans. Under the parameterisation of ELmojtaba et al. (2010a)
the removal of this secondary population was beneficial to humans although
the reduction in RNGM0 was relatively paltry (3.4 down to 2.3) and indicates
that whilst infection is boosted by the animal reservoir, it is not sustained
by it.
5. Conclusions
Despite model predictions based on well defined (average) parameter es-
timates and scenarios, the operational realities on the ground are somewhat
different adding a variable complexity that are difficult to capture. VL disease
on the ISC has been targeted for elimination as a public health problem, but
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there are still many facets of this infection which are not well understood.
In particular the progression of disease through different stages, including
asymptomatic infection and PKDL, is unclear, especially in relation to diag-
nosis and infectivity. Recent efforts to control VL on the ISC seem to have
had success, prompting the original goal of elimination as a public health
problem to be brought forwards from 2020 to 2017 (WHO, 2013; Boni et al.,
2014). However, there are also indications that caution as well as optimism
should be exercised; modelling and transmission studies have indicated a
credible possibility that asymptomatically infected individuals might hinder
elimination efforts or obscure the true number of those with Leishmania in-
fection.
Treatment of people presenting with KA is central to the current inter-
ventions. Models disagree on whether this intervention alone is adequate to
achieve control and sufficiently reduce incidence. This disagreement hinges
on the relative proportion of transmission to sandflies due to symptomatic
people who are then treated. If KA patients are responsible for the majority
of transmission, then treatment will have a big impact on onward transmis-
sion. The evidence for this situation is indirect and largely reliant on the
spatio-temporal clustering of KA cases and the long period cycles seen at
regional levels; both of these are more easily explained if KA cases are re-
sponsible for transmission. However, if the majority of transmission is due to
asymptomatic infections, then treating KA patients promptly will have little
impact on transmission. There is less evidence for this situation, but it is
not unlikely if there are large numbers of asymptomatic infections that trans-
mit to sandflies at a low rate. This situation highlights the need for more
accurate data on the natural history and relative infectiousness of different
infection states.
Looking forwards, model predictions of vector control consistently result
in effective control of disease, not just on the ISC but in regions affected
by ZVL too. IRS seems to have the maximal benefit amongst strategies
including bed net use and other EVM. However it is emphasised that these
modelling results do depend critically on the infectivity of different disease
states, the effectiveness of IRS and the vector response to EVM. Again,
there is a paucity of data to support parameterisation of these processes in
any model. With control of sandfly populations appearing pivotal in the
elimination campaign, it will be especially important to improve both our
understanding of sandfly biology and how transmission may change through
the course of a year. Future modelling of VL in humans could utilise the
66
basic frameworks set out by those who have previously modelled seasonality
of sandflies in ZVL as well as the wider literature on seasonal dependence of
other disease vectors.
Modelling of VL in dogs has shown that the sensitivity and specificity
of diagnostics are likely to have a direct impact on the success of culling
strategies for dogs, and hints at the wider importance of accurate diagnostic
tools in reporting and control human disease. Caution must be taken with
modelled intervention comparisons because, in reality, some interventions
may be far easier to employ (to the extent needed) than others. This is
highlighted in the canine VL papers which have mixed suggestions for the
best intervention.
The current intervention programmes focus on eliminating VL disease as
a public health problem rather than considering achieving a break in trans-
mission. Elimination as a pubic health problem is technically described as
control in that continued efforts are required to maintain the lower incidence.
As the numbers of cases on the ISC falls towards the target of 1 per 10,000,
clinical awareness is likely to fall. Additionally, if there is population (herd)
immunity that currently reduces transmission (because a proportion of the
population are immune), then this too may wane over time. As a conse-
quence it is possible that there will be an increasingly susceptible population
with a less alert medical and public health system and on-going transmission,
all within a matter of years. This is the situation in which transmission can
resurge and potentially large epidemics occur. Therefore it is important to
understand transmission rather than focus solely on diseased individuals to
ensure recrudescence does not occur.
There are several key knowledge and data gaps which have been identi-
fied within this chapter. There is a need to better understand the biology of
disease including disease progression (by determining markers to differenti-
ate self-clearing asymptomatic infection from those that progress to disease),
infectivity of all infected individuals, and prospects for human vaccine de-
velopment. However there is also a need to better inform models with data;
models need to consider time-dependent transients, which emphasises the im-
portance of longitudinal data. The important dimensions of heterogeneity,
including individual-level differences and larger-scale spatial aspects, need to
be incorporated in models if they are to capture key aspects of transmission
dynamics.
Unsurprisingly, the number of models of visceral leishmaniasis is ex-
tremely low, especially when compared to the vast modelling literature for
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other vector-borne disease such as malaria and dengue. However, the existing
models do address a range of important questions such as the level of under-
reporting of VL disease and relative impact of different interventions. Future
models must be fitted to high quality contemporary data sets in order to
ensure the highest level predictive value of the results and hopefully, through
good communication between modellers and the larger VL community, the
key outstanding questions may be addressed.
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Table 5: Summary of mathematical modelling articles of VL extended from Rock et al. (2015a).
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